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Rett syndrome (RTT), a rare but severe neurological disorder is associated with a 
mutation in the methyl CpG binding protein 2 (MECP2) gene on the X chromosome 
occurring in 1:9000 live female births. Apparently normal development is followed by a 
regression in hand and communication skills, and subsequent development of hand 
stereotypies and abnormal gait. These characteristics are usually accompanied with 
comorbidities such as sleep problems and scoliosis. Over 80% of RTT individuals have 
specific sleep problems including night waking and difficulty falling asleep.  
Using a cross-sectional survey design, this study explored types of sleeping problems 
observed and relationships with variables such as age and genotype; and finally 
investigated specific management strategies. Participants mainly comprised families 
registered in the International Rett Syndrome Phenotype Database (InterRett) with a 
child of any age who has a confirmed RTT diagnosis and/or a MECP2 mutation. New 
families were invited via InterRett Facebook page and parent Listserve RettNet. A web-
based questionnaire using freely available software, “REDCap” was developed to 
collect data. The independent variables tested were age group, mutation type, epilepsy, 
scoliosis, mobility and uses of sleep hygiene strategies while dependent variables tested 
include the presence, nature and frequency of sleep problems. Descriptive statistics 
were used to examine each variables and regression models including simple logistic 
regression and multinomial logistic regression models were employed to investigate the 
relationships between phenotype, treatments and sleep problems.  
Findings from this study showed sleep problems were more pronounced in RTT cases 
than in the general population. The prevalence of most sleep problems were higher in 
younger children and those with a p.Arg294* mutation. Other covariates including 
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severe seizure activity was associated with poor sleep by taking into account the effect 
of age, mutation type, scoliosis and mobility. Non-pharmacological interventions were 
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Chapter 1: Introduction 
 
Rett syndrome is a rare genetically caused neurodevelopmental disorder affecting 
1:9000 per live female births by the age of 32 years (1). It is a complex disorder with 
poor functional abilities, cognitive impairment and the development of comorbidities 
such as scoliosis, epilepsy, breathing irregularities and poor sleep. 
Problems with sleep are challenging in day to day life, not only for individuals with an 
intellectual disability such as Rett syndrome but also for their families. This thesis will 
investigate sleep problems in Rett syndrome.  
1.1 Intellectual disability 
 
Intellectual disability (ID), refers to a deficit in intelligence quotient (IQ) and adaptive 
skills with an early age of onset (2). It may be associated with difficulties in achieving 
tasks of daily living such as communication and mobility (2). Based on the severity and 
IQ levels, ID has been categorised as mild, moderate, severe, profound or unclassifiable 
(2, 3). In addition, ID is further grouped into syndromic and non-syndromic intellectual 
disability with Rett syndrome as an example (3).  
The aetiology of intellectual disability is multifactorial with a significant proportion of 
individuals having a genetic cause such as Down syndrome, Fragile X syndrome or Rett 
syndrome (3, 4). These syndromes are often associated with dysmorphic features or 
physical comorbidities. For example children with Williams syndrome have 
characteristic elfin like- faces and those with Angelman syndrome an open mouth and a 
jerky gait ataxia (5, 6). Epilepsy and cerebral palsy may also be present in some 
individuals with ID, contributing to the psychiatric conditions (7). Comorbidities 
including sleep problems, respiratory infections, scoliosis, and osteoporosis may also 
occur (4, 8).  
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Among the above mentioned comorbidities, sleep problems are common (8, 9). In 
adults with ID, less REM sleep and more night wakenings have been reported compared 
to adults without ID (10, 11). In addition, Piazza et al. (1996) reported that individuals 
with ID had less total sleep time when compared to a normal population. In addition, 
delayed sleep onset, persistent night waking or early waking were observed (12). 
Recent published research has shown that non-pharmacological treatments have a role 
in managing sleep problems in children with developmental disabilities (13). 
Behavioural sleep interventions including chronotherapy, sleep scheduling and fading 
bedtime procedure are being suggested (13-15). Pharmacological interventions such as 
melatonin and valproate are also being used (16). Nevertheless, there are few 
randomized trials on interventions tested on participants with any particular disorder. 
1.2 Rett Syndrome 
 
RTT is a rare but severe neurodevelopmental disorder found primarily in females (17-
19). It is mostly associated with a pathogenic mutation on the MECP2 gene (20). 
Affected individuals have an apparently normal period of early development followed 
by a regression in hand function and communication skills, and subsequent 
development of hand stereotypies and abnormal gait (21). These characteristics are 
usually accompanied by comorbidities such as epilepsy, scoliosis, sleep problems and 
are unique to girls and depend on the age when first seen (21, 22). 
1.2.1 Natural History 
 
RTT was initially described in 1954 by Andreas Rett, a paediatric neurologist, in 
Vienna. He noticed two girls seated in his waiting room exhibiting the exact same 
behaviours and movements (23, 24). His early observations on early developmental 
regression with repetitive hand stereotypies, hand and gait apraxia (22) were later 
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published in the German medical literature in 1966 (25). Less than a decade later, the 
syndrome was described in great detail under a misleading heading as “cerebral atrophy 
and hyperammonaemia”, published in an English literature in 1977 with a report on 21 
cases (26). However, Rett’s works were largely unnoticed. Independently, in 1978, 
Japanese scientist Ishikawa and his team also reported similar features to those observed 
by Rett in three Japanese girls (27).  
Hagberg first noticed the symptomatology of RTT in a 3 ½ year old Swedish girl named 
“Anne Marie Vesslund”, and nicknamed this rare syndrome after her as “Morbus 
Vesslan”. Unaware of Rett’s work and the Japanese report, Hagberg described the 
clinical features observed in 16 Swedish girls in 1980 at a meeting in Manchester for the 
members of the European Federation of Child Neurology Societies (22). The turning 
point for awareness of  RTT occurred in 1983 when Hagberg et al published their 
works which demonstrated the clinical features in a pooled series of 35 girls from 
Sweden, France and Portugal (22-24, 28).  
All girls presented with normal development for the first 7-18 months of age followed 
by a rapid deterioration both mentally and behaviourally. The deterioration was thought 
to progress to severe dementia, acquired microcephaly, loss of purposeful hand with 
autistic behaviour, truncal ataxia and gait apraxia. Other symptomatology included 
spasticity, vasomotor disturbances and epilepsy. These features have all contributed to 
the current clinical diagnostic criteria (28, 29). Hyperammonaemia was another 
observation that Rett reported in his findings in 1977 (26). Nevertheless, Hagberg 
disagreed stating that it is no longer considered as a sign of the syndrome since the 4/54 
cases done by Rett only showed this sign and was absent in the girls for the study 
conducted by Hagberg et al (1983). The paper concluded suggesting dominant mutation 
on one X chromosome caused early aborted male hemizygotic conceptus (28).  
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The published work by Hagberg and this group led to the first Rett syndrome 
conference and the first North American conference on Rett syndrome that took place in 
1984 and 1985 respectively (23). Further to these events was the establishment of a 
parental support group known as the International Rett Syndrome Association (IRSA) 
(22-24).  
Additional clinical studies in the late 1980s provided more insight about this unique 
syndrome (30, 31). Studies conducted in the UK (30) and America (31) found similar 
clinical observations to Hagberg. However, the American study alone specifically 
reported the presentation of hand stereotypies such as hand wringing and sleep 
disturbance in contrast to the UK study (31).  
Only three were published between 1966 and 1983, compared with ~300 less than a 
decade later from 1984 to 1991 (23). It was the contribution of ongoing research studies 
that developed a successful pathway to what is now widely known as Rett syndrome. 
1.2.2 Prevalence 
 
The first prevalence study was conducted in Southwest Sweden in 1985 by Hagberg, 
who found that the prevalence of Rett syndrome was 0.65 per 10,000 girls aged 6 to 17 
years (32). It is challenging to estimate the incidence and prevalence of a rare disorder 
but a population-based study can give the most accurate measurement (19, 32, 33).  
In 1993, the first population-based study was performed in Texas by Kozinetz et al. The 
prevalence of classic RTT cases was found to be 0.44 per 10,000 girls, aged between 
two to 18 (34). Later, Leonard et al (1997) investigated the incidence and prevalence of 
RTT in Australia. Participants for this study were determined through the Rett 
Syndrome Association of Australia and the Australian Paediatric Surveillance Unit. A 
prevalence of 0.67 per 10,000 females aged between five and 18 years was found (35). 
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An updated prevalence was reported by Fehr et al in 2011 looking at the incidence and 
prevalence in Australia using a population-based data source. With 349 confirmed cases 
born between 1976 and 2006, the incidence of RTT diagnosis was 1 in 9000 live female 
births by 32 years of age (19). 
1.3 Classifications of RTT 
 
Rett syndrome has been classified into two types: classic and atypical RTT. Girls 
affected with classic RTT have a normal prenatal and perinatal development between 6- 
18 months of age and meet the essential clinical criteria for the diagnosis (32, 36, 37). 
Those with atypical RTT meet some of the essential criteria and also some of the 
supportive criteria (38). This group tends to develop the signs of Rett syndrome either 
very early or regression may be later. Medical literature, from early as 1985 have 
discussed different types of Rettoid phenotypes: forme fruste, congenital, early seizure 
onset, late regression, preserved speech and male variant (22, 38-41) 
1.4 Diagnosis of RTT 
 
Diagnostic criteria were first published in 1985 by Hagberg and his colleagues (22, 40). 
There have been several iterations and the most recent version of clinical criteria for 
RTT was published in 2010 (21) and it includes the necessary, supportive and exclusion 
criteria.  
1.4.1 Diagnostic criteria 
 
The main criteria are well described from early research with a normal prenatal and 
perinatal history followed by a developmental regression including loss of acquired 
language and purposeful hand use; and the development of impaired gait and hand 
stereotypies such as wringing and washing (21, 40). These four criteria suggest a classic 
case of RTT. Exclusion criteria was developed to ensure that neurological problems, for 
6 
 
example, brain injury following trauma, severe infections or other progressive 
neurological disorders are not the real cause for the clinical presentation of RTT. 
Supportive criteria were further established to help diagnose atypical cases even though 
these features are observed in classic RTT cases. It includes breathing irregularities; 
bruxism; impaired sleep pattern; muscle wasting; vasomotor disturbances; scoliosis; 
growth retardation; small and cold hands and feet; ; laughing and/or screaming spells; 
diminished pain responses and ; intense eye contact (21). In order to make a diagnosis 
for atypical RTT cases, a period of regression, two out of four main criteria and five out 
of 11 supportive criteria must be present. Since a genetic cause of RTT is now known 
(20), the above mentioned clinical criteria are supported by genetic testing where a 
positive MECP2 mutation confirms the clinical diagnosis. 
1.5 Clinical stages of RTT 
 
To better understand the appearance of characteristic features, in 1986, a proposed 
staging system was suggested by Hagberg and Witt Engerstrom during their evaluation 
in 29 Swedish girls with RTT and was later updated by Hagberg in 2002 (38, 42).  
Stage l, known as Stagnation stage, is seen in girls aged between 6 months - 1 ½ years 
with a duration course of several months. In this stage, developmental arrest occurs, 
particularly in gross motor abilities and symptoms are non-specific. Stage II, known as 
rapid destructive stage, is a period of regression of acquired abilities where patients 
show a loss of hand and communication skills and changed personalities. During this 
stage, clinical features such as hand stereotypies, autistic features and seizures are 
observed.  Duration of this stage is estimated to last between weeks and months, with an 
age border of 1-4 years (22, 38).  
Stages III and IV are a period after regression. Stage III is known for Pseudostationary 
stage and is regarded as a ‘silent’ period where autistic features are worn out, but are 
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prominent with seizures, gait apraxia, truncal ataxia, hand stereotypies and severe 
mental retardation. The duration of this stage lasts for years, more specifically, from 
preschool to early school years. It is in this stage where some of the original abilities are 
regained. The last stage, motor deterioration stage, has duration for decades with 
patients aged between 5-25 + years. While in this fourth stage, previously ambulant 
patients become non-ambulant. Clinical features such as scoliosis and cachexia are 
prominent while seizures tend to lessen. In addition, spasticity and muscle wasting gets 
worsened during these years (23, 36, 38, 42). However, this framework for 
understanding the longitudinal course of RTT has not been validated with a longitudinal 
study in a population-based sample. 
1.6 Genetic origin of RTT 
 
In 1999, Amir et al discovered by using a systematic gene screening approach that X-
linked dominant mutation within the Methyl-CpG Binding Protein 2 (MECP2) gene on 
the long arm of X chromosome at Xq28 was associated with RTT (20). RTT mainly 
affects females but is usually lethal in hemizygous males including neonatal 
encephalopathy with death within 1-2 years after birth (43). 
1.6.1 The methyl-CpG-binding protein 2 (MECP2) gene 
 
The MECP2 gene encodes the protein MeCP2. It is widely present throughout the body, 
particularly in brain cells. The protein is important for the brain development, 
particularly for the maturation of nerve cells. MeCP2 protein functions by “repressing” 
several genes that prevents those genes from making unwanted proteins. The MeCP2 
protein acts by binding to methylated DNA, specifically to the methylated CpG 
dinucleotides’ region, thereby altering gene expression (44, 45). The gene includes a 
methyl CpG binding domain and a transcription regression domain where mutations in 
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these regions result in severe RTT phenotypes (46, 47). Mutations in the MECP2 gene 
are a result of the changes occurring in single DNA base pairs (SNP), insertions or 
deletions of DNA in the gene, or truncation along the different points on the gene (45). 
MeCP2 gene is expressed throughout the body, especially in the central nervous system 
(48). In order for this part of the nervous system to function properly, the homeostatic 
regulation of MeCP2 is essential. MeCP2 acts by up-regulating or down-regulating 
other genes and by forming synaptic transmission, including spontaneous 
neurotransmission and short-term synaptic plasticity within the central nervous system 
(45). Recent research indicated that MeCP2 protein is not only involved in repressing 
but also activating other genes but this remains controversial (49). 
A population based study using 272 individuals from Australian Rett Syndrome 
Database found that the most frequent mutation types in the MECP2 gene that occurred 
in RTT individuals: p.R106W; p.R133C; p.T158M; p.R168X; p.R255X; p.R270X; 
p.R294X; p.R306C and C-terminal deletions (46). 
1.6.2 Genotype-phenotype relationship 
 
There are a wide range of phenotypes presented in individuals with RTT due to gene 
expression that results from the mutation in the MECP2 gene (45). The relationships 
between genotype and phenotype have led to conflicting results over the past years 
probably due to the inconsistency in categorising different types of mutations.  
An Australian population-based study conducted in 2004 looked upon the genotypic and 
phenotypic characteristics in females with RTT (50). Mutations in the nuclear 
localisation signal (NLS) region of the transcriptional repression domain (TRD) were 
found to be severe and that mutations in the methyl-CpG-binding domain (MBD) 
retained greater voluntary hand use in comparison to TRD. In contrast, less severe 
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phenotype was observed in the C-terminal region. Further, out of the most common 
mutation types, R270X was found to be most severe which was located in the NLS 
region of the TRD mutations (50). 
Larger sample size studies are suggesting that there are relationships between genotype 
and phenotype. For example, individuals with the p.R133X, p.R294X and p.R306C 
mutations usually have a milder phenotype whereas those with a p.R255X, p.R270X or 
p.168X mutation usually have a more severe phenotype (21, 46). 
1.7 Comorbidities of RTT 
 
The core characteristics of RTT are usually accompanied by co-morbidities which are 
associated with the supportive diagnostic criteria. The presentation of these 
characteristic manifestations is unique to each RTT individual and the overall severity 
of the conditions are exceedingly variable across the affected individuals (51). This 
section summarises common comorbidities and the co-morbidity of sleep is discussed in 
detail in section 2.0. 
1.7.1 Epilepsy 
 
Manifestation of seizures varies among individuals and a mixture of general and partial 
seizures are observed in RTT females (22). An Australian population-based study 
showed that seizures most commonly occurred between 7 to 12 years of age and 
occurred less frequently in individuals with p.R249X and p.R255X mutation types (52). 
A recent study using a cross sectional cohort of adults from the Australian Rett 
Syndrome Database and the international database InterRett indicated that around 64% 
of RTT women were currently receiving treatment for epilepsy (51) suggesting that this 
comorbidity often persists into adulthood. 
10 
 
1.7.2 Gastrointestinal disorders 
 
Problems with gastrointestinal function are common in RTT. In a US based survey 
conducted in 2012 involving 983 RTT cases, around 59% of females were affected by 
one or more problems with gastrointestinal problems including dysmotility disorders 
affecting 92% (53). In a recent cross sectional cohort study, there was a high prevalence 
for constipation (83%) and abdominal bloating (53%) (51).  
1.7.3 Growth retardation 
 
The majority of females with RTT have somatic growth failure. Hagberg et al. (1983) 
first reported growth arrest of the feet in girls with RTT (28). Research shows that 
growth abnormalities are associated with feeding difficulties and malnutrition (54). 
Both nutritional and non-nutritional factors are thought to contribute towards growth 
abnormalities. Nutritional factors include gastrointestinal problems, reduced food intake 
and impaired bowel function while non nutritional factors relate to the mobility and age 
of the affected individual and disease severity (54). A recent study by Anderson et al 
(2014) reported that slightly more than half of  RTT women were underweight (52.8%) 
(51). 
1.7.4 Altered bone health 
 
Reduced bone density and insufficient bone minerals are observed in individuals with 
RTT and these conditions tend to vary across different MEPC2 mutation types. 
Individuals associated with p.R270X and p.R168X mutations types had the increased 
risk of fractures (53). A population based study conducted by Downs et al (2008) found 
that the risk of bone fracture was nearly four times higher in individuals with RTT in 





Scoliosis is one of the most common and problematic co-morbidities found in females 
with RTT. Scoliosis in RTT is believed to be of neurogenic origin and thus reveals 
during early life (56-58). Scoliosis impacts the posture, mobility and digestion of the 
affected individual and could have adverse effects such as pain, and respiratory 
dysfunction (56, 58). A 2006 population-based study showed that 75% of subjects 
developed scoliosis by the age of 13 (57). 
1.7.6 Breathing irregularities 
 
Abnormal breathing patterns commonly occur in RTT. Affected individuals may 
present with different forms of irregular breathing patterns such as episodes of 
hyperventilation and breath holding (59). A 2014 study of adults with RTT found that 
abnormal breathing patterns including hyperventilation and breath-holding were 
reported for two thirds of women (66.4%) (51). 
1.8 Sleep 
 
Sleep is a physiologic behaviour in humans (39) and can be defined as “a reversible 
condition of reduced responsiveness usually associated with immobility” (60). Theories 
have developed to suggest why this adaptive behaviour has evolved in humans. For 
example, studies have suggested that sleep is a period where learned experiences are 
consolidated and also a period which restores brain energy following periods of 
wakefulness (61, 62). 
There are two types of sleep: REM (rapid eye movement) sleep and non-REM (non- 
rapid eye movement). REM sleep is characterised by sudden, rapid movement of the 
eyes and muscle atonia. It is in this type of sleep where dreaming is experienced. Non-
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REM (non- rapid eye movement) stage of sleep, is characterised as when a person has 
no awareness of the surroundings (60, 63). 
Among these two types, NREM sleep is further divided into four stages: 1-4 stages of 
sleep. Stage 1 represents a “light sleep” where a person could be easily aroused and can 
be scattered with REM (rapid eye movement) sleep. In the initial sleep-stage cycle, this 
sleep stage only lasts for up to seven minutes. Stage 2, is when a person in this stage 
requires intense stimuli to be awakened and has duration between 10 to 25 minutes. 
Stages 3 and 4 are represented as slow wave sleep (SWS). Both stages are characterised 
with an increased amount of high-voltage and slow delta waves activity. However, the 
duration of both stages differ. Stage 3 lasts for only few minutes while stage 4 lasts 
approximately 20 to 40 minutes. It is in stage 3 where sleep problems such as night 
terrors, sleepwalking and bruxism occurs (60, 63). Studies using sleep macrostructural 
parameters have shown that individuals with RTT have an abnormal REM/NREM 
rhythm due to an abnormality in the activation of monoaminergic and cholinergic 
systems (64).   
1.8.1 Neurophysiology of sleep in relation to RTT 
 
Sleep is controlled by two types of neurons: aminergic neurons situated in the brain 
stem and midbrain and cholinergic neurons in the pons (39, 65). Aminergic neurons are 
described as “wake-on-and-sleep-off cells” and are responsible for desynchronizing 
EEG (electroencephalogram) during wakefulness. High aminergic activity is observed 
while awake but is reduced and absent during NREM and REM sleep. Cholinergic 
neurons are also responsible for desynchronizing EEG during wakefulness. In contrast 
to Aminergic neurons, cholinergic neurons are expressed at a maximum during 
wakefulness and REM sleep but are absent during NREM sleep (66). A recent 
polysomnography study showed that a deficiency in the monoaminergic neurons during 
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the early developmental stage of life cause sleep disorders such as night awakenings and 
are expressed in neurodevelopmental disorders such as RTT (64).  
Two internal mechanisms are associated with sleep regulation: homeostatic processes 
(affected by the time spent awake) and circadian system (biological clock) (60, 67). The 
first process involves regulation of sleep homeostasis when awakened. Adenosine, a 
compound form of neuronal energy metabolism is believed to be the factor that drives 
us to sleep (66, 67). While the body is awakened, adenosine level rises by the 
cholinergic system and reaches a point where it signals the body for a shift towards a 
sleepy state. Once the body is in the sleep state, adenosine gets broken down (68). 
The second process involves the biological clock. Biological clocks are genetically 
controlled cellular mechanisms which help the metabolism by adapting to the 24 hour 
light and dark cycle (60, 69). The release of the chemicals, melatonin and cortisol by the 
body are controlled by the body’s biological clock. When the environment gets dark, 
melatonin, a hormone secreted by the pineal gland, is released into the bloodstream. 
Melatonin initiates sleep onset and promotes drowsiness.  Research has shown that 
when melatonin levels reach the peak by evening, it prepares the body for sleep. Once 
the sleep/darkness period ends, melatonin levels decline while another hormone called 
cortisol is released with the opposite reaction to melatonin. This hormone helps the 
body to wake up (70). In genetic syndromes such as RTT, Melatonin is used as a 
pharmacological strategy to manage sleep problems (17). 
The timing and rhythm of the biological clock changes with age. Sleep amounts are 
greater during neonatal periods, particularly during rapid brain development (71). This 
is clearly evident in early life, as newborns sleep an average of 16 hours a day in 
comparison to adults (60). 
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1.8.2 Sleep problems in genetic disorders 
 
Past research has shown sleep disorders occur with a higher severity and frequency in 
persons with developmental disabilities (14, 71). Sleep issues occur particularly 
frequently in genetically caused syndromes including Prader-Willi syndrome, 
Angelman syndrome, William’s syndrome and Rett syndrome (71, 72). 
Deletion or inexpression of genes on chromosome 15 causes Prader-Willi syndrome 
(PWS) in individuals. Sleep difficulties such as excessive daytime sleepiness and 
daytime napping are reported in PWS patients with a prevalence rate of 35-45%  (73). 
In Angelman syndrome, caused by a chromosomal deletion in the 15q11-13 region of 
the maternally derived chromosome, affected individuals experience night waking and 
early waking (71, 72). In Williams syndrome (WS), a disorder resulting from a deletion 
of chromosome 7q11.23 involving the elastin gene, sleep problems including greater 
bedtime resistance, sleep anxiety, night waking and daytime sleepiness are common 
(74). 
1.8.3 Sleep problems in RTT 
 
RTT individuals are shown to have specific sleep related problems unlike any other 
neurological disorders (75). Occurrence of sleep dysfunction was initially reported in 
early clinical studies as prolonged night laughing episodes or night screaming and was 
regarded as an early sign of regression (31, 76). Later, impaired sleep patterns were 
included as one of the 11 supportive diagnostic criteria (17, 21). Sleep problems 
associated with RTT include night laughing, night screaming, night seizures, teeth 
grinding, spells of screaming for no apparent reason during night, and frequent daytime 
naps (17, 18).  
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Sleep dysfunction was reported in studies as early as in 1980s. In 1986, Naidu et al 
conducted a clinical study by using a large cohort of individuals with RTT based in US 
(31). They evaluated 70 females with RTT varying in age between 2.5 to 34.5 years. 
Out of 70 females, 40 exhibited dysfunctional sleep. The notable sleep problems were 
night waking and night screaming/crying and reported that these sleep problems were 
noticed in the 2 to 5 years old age group (31). 
Additionally, a paper published by Nomura et al in 1987 investigated the sleep-
wakefulness rhythm in a 4 year old girl. Irregular sleep onset and periods of “profound 
naps” were observed in the girl and did persist even after 4 years of age. In addition a 
delay in the maturation of circadian rhythm was found (77). In another study, Glaze et 
al observed abnormal sleep in 11 patients and found that older girls with RTT had 
decreased amount of night time sleep (78). 
Further, EEG studies have also reported sleep disturbances in girls and women with 
RTT. Niedermeyer et al (1986) observed abnormal EEG activity during sleep in girls 
with RTT (79). In addition, Glaze et al. found in his 11 patients that there was a 
decrease in REM sleep, an increase in stage 2 sleep and a decrease in sleep latency (78). 
In contrast to these findings, Nomura et al reported an increase in REM sleep 
particularly in older age and reported irregular sleep onset and increased daytime sleep 
in individuals with RTT (41).  
Variation in these above mentioned findings highlights the usage of different research 
methodologies. For example, the study conducted by Naidu et al (31) did not use a 
direct measurement of sleep but parental report. Also, the EEG studies conducted by 
Glaze et al and Nomura et al used small sample sizes and short durations of sleep 
observations to measure the sleep patterns. These factors all contribute to the limitations 
in finding more information on sleep difficulties in individuals with RTT.  
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However, a US based clinical study published in 1990 investigated sleep/wake patterns 
and sleep problems in classic RTT cases by using a direct observation procedure on a 
slightly larger cohort (n=20) (80). Momentary time sampling procedures were used by 
the parents in order to document the sleep/wake patterns. Total sleep time and excessive 
day time sleeping was longer while night time sleep was shorter in duration when 
compared to the normal population. A number of factors such as delayed sleep onset 
(67.8%), frequent night waking (20.9%) and early waking (24.5%) contributed towards 
the decreased night time sleep (80). In addition, a correlation between sleep patterns and 
age was observed. Night sleep was negatively correlated with age, daytime sleep was 
positively correlated and total sleep time was not correlated to age (80).  
In 2001, Ellaway et al conducted the first study in assessing the sleep characteristics of 
RTT by using a large cohort of females (n=83) from the Australian Rett Syndrome 
Database. The study used a simple, cost effective and reliable sleep diary for seven 
consecutive days and nights and was measured against the normal population. This 
study reported that total sleep time and excessive daytime napping increased with age 
when compared to the normal children. The authors confirmed that delayed sleep onset 
and night waking were prevalent in females with RTT (81).  
An Australian population based study (n=273) by Young et al in 2007 aimed to 
investigate the prevalence of sleep problems in RTT and to further investigate the type 
and frequency of sleep problems, and their relationships with age and MeCP2 mutation 
types. Sleep problems varied with age and mutation types. The study reported on 
specific sleep problems such as night laughing (60%) and night screaming (35%) to be 
most prevalent. In addition, daytime naps, night laughing, night screaming, night 
seizures and teeth grinding also appeared frequently (18).  
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Adding on to the information of sleep problems in RTT, a case-control study using 
polysomnography was performed in 2013 looking at the sleep macrostructural 
parameters in 13 RTT cases. A great impairment was observed in sleep macrostructural 
parameters by an increased night awakening and decreased REM sleep. However there 
were certain limitations for this study. The study sample was small and all individuals in 
the sample group reached the advanced clinical stage of RTT and a follow-up 
evaluation was not performed (64). 
In 2014, a longitudinal, population-based study was performed including 320 families 
with a child with RTT who was registered with the Australian Rett Syndrome Database. 
Among the specific sleep problems, night laughing (77%) and night screaming (49%) 
was highest. Further, prevalence of any sleep problems was higher in the younger age 
group (0-7 age) and in individuals with a large deletion mutation (17).  
1.8.4 Prevalence 
 
Sleeping problems have been observed in approximately 80% of girls and women with 
RTT and the prevalence decreases with age. (17). Two recent longitudinal, population-
based studies involving cases registered within Australian Rett Syndrome database 
showed that the prevalence of any sleep problem differed between girls and women, and 
does vary with age and mutation type (17, 18). 
1.8.5 Relationships with age 
 
The frequency of sleep problems varies among different age groups of RTT but 
generally decreases with age. A recent Australian population-based study found that the 
frequency of any sleep problem was highest when younger, 0-7 age group, especially 
night laughing and night screaming. In contrast, night waking was common among the 
older age groups. (17). 
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1.8.6 Relationships with genotype 
 
The type and frequency of sleep problems in RTT individuals vary among genotypes of 
MECP2 (17, 18). A 2014, an Australian population based study consisting of 320 RTT 
confirmed cases showed the highest frequency of any sleep problem was seen in 
individuals with a large deletion (94%), p.R270X (92%) and p.R294X (91%) mutations. 
Moreover, the frequency of specific sleep problems varied across the mutation types. 
Night laughing was observed to be highest in those with a large deletion (90%) and 
p.R168X (78%) mutation types while night screaming was more frequent in p.R270X 
(57%), p.R306C (51%) and large deletion (51%). Night waking was reported to be 
lowest for early truncating (50%), C-terminal deletion (58%) and p.R306C (57%) 
mutations (17). 
1.8.7 Sleep management in RTT 
 
A small number of studies have investigated the management of sleep problems in girls 
and women with RTT including both pharmacological and behavioural strategies (17). 
1.8.7.1 Behavioural interventions 
 
Studies have suggested that behavioural treatment to be effective in reducing sleep 
disturbances (13, 82-84). Early studies since the 1980’s have described behavioural 
methods being used as management techniques for sleep disorders (85). Behavioural 
treatments in RTT include bed time fading procedures, and chrono therapy that could 
reduce time to sleep onset (17). Anecdotal reports from the review of RettNet, an online 
forum for those affected by Rett syndrome and hosted by Rettsyndrome.org, indicated 




Numerous studies have shown using a variety of behavioural treatments in the general 
paediatric population for childhood sleep problems. Implementation of behavioural 
techniques for sleep problems in general began around 1950’s. A single case study was 
conducted on a 4 year old boy who exhibited prolonged tempers at bed time although 
without any defined medical condition. This tantrum behaviour was eliminated by 
extinction procedures where the parents reduced attending the child after wishing good 
night (86). Later on, several studies reported on varying success in treating adults with 
insomnia and autism. Methods included relaxation, stimulus control, and parent 
behaviour and child response (87-89). 
In 1985, Richman et al conducted a pilot study looking at the efficacy of generalised 
behavioural strategies in children with sleep problems. Behavioural methods included 
withdrawal of positive reinforcement by parents such as star charts; shaping, making an 
early bedtime; and cueing. Out of the 35 children, 77% showed an improvement with 
their sleep problems. Regardless, the study excluded children with severe intellectual 
disability. Thus, causing a further limitation to look at the effectiveness of behavioural 
methods being administered in children with sleep related specific disorders (84).  
In relation to abnormal sleep problems observed in children with developmental 
disabilities, few studies have shown an improvement in sleep problems by using 
behavioural methods as the management technique. Behavioural methods such as 
chronotherapy, sleep scheduling, bedtime fading and light therapy have been used to 
diminish aberrant sleep patterns and specific sleep problems (13, 15, 16, 82-84, 90, 91).  
Chronotherapy: This procedure is used to reset the biological clock, or circadian clock, 
by systematically changing either the child’s bedtime or wake-up time (13, 14). Early 
studies have reported on the effectiveness of chronotherapy on sleep problems. A study 
conducted by Okawa et al (1987) showed chronotherapy being successful in treating 
four congenitally blind children who had moderate to severe ID (82). Also, Piazza et al 
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conducted a study in 1998 using chronotherapy in an eight year old girl with severe 
autism. The four month follow up data reported that improvement was noticed for 
irregular sleep onset times, night and early waking and shorter total sleep time (91).  
Sleep scheduling: Refers to setting scheduled fixed times when going to bed and for 
waking (13, 14). In a study by Espie and Wilson (1993) sleep scheduling was found to 
be effective in reducing sleep problems exhibited by five children and adults who 
presented with a mild to profound mental retardation (92).  
Bedtime fading: The procedure involves setting a bedtime around the time when sleep 
onset occurs and then fading it, as in delaying the bedtime if a shorter time for the 
initiation of sleep does not occur (13, 14). Few studies have used this method in 
managing sleep problems. Two studies conducted by Piazza et al., (1991) showed that 
the individuals with developmental disabilities initially showed a decreased night time 
sleep and increased daytime sleep. Upon the treatment, night time sleep was increased 
while daytime sleep got reduced. Some individuals showed an improvement in night 
waking (83, 90). Later in 1996, night time behaviours observed in Sanfilippo syndrome 
children such as staying up all night and crying during the night was shown to be 
improved using the bedtime fading procedure (93).  
Light therapy: It is a procedure where an individual is exposed to bright light in the 
morning (13). An uncontrolled case study was published in 1998 to show the effect of 
light therapy on sleep problems. In a study by Short and Carpenter, light therapy was 
applied on a 34 year old man with profound mental retardation. Within two weeks of 
the treatment, daytime sleep was reduced and also stabilised his sleep patterns (94). 
However, studies on these behavioural methods specific to sleep problems in RTT 
patients are limited except with bedtime fading procedure. A single case design study 
was performed by Piazza et al in 1991. The investigation involved treating three girls 
with Rett syndrome by using a bedtime fading procedure with response cost. As 
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mentioned earlier, fading consists of delaying the bedtime if the child did not show a 
short latency to initiate sleep onset. While, response cost involved removing the child 
from the bed and keeping her awake for one hour if sleep wasn’t initiated within 15 
minutes of the normal bedtime. The treatment was shown to be effective in which more 
regular sleep patterns were observed in the girls by an increased night time sleep and 
reduced daytime sleep. It further reduced night time behaviours such as night waking 
(83). Nonetheless, studies are still lacking to show the efficacy of using this specific 
treatment in a large sample of individuals with RTT. 
However, evidence is still lacking to show the effectiveness in treating RTT individuals 
with behavioural methods. In addition, studies conducted recently do vary in their view 
of understanding the necessity of using behavioural type therapeutic interventions. 
1.8.8 Pharmacological interventions 
 
Pharmacological treatments to treat individuals with RTT include sleep medications, 
e.g. melatonin (95) and chloral hydrate, 5-hydroxytryptophan (5-HTP) for reduced time 
to sleep onset and non-specific sleep medications, e.g. risperidone (17). The most recent 
large scale study in 2014 indicated that the most commonly used medication was 
melatonin, accounting for 17.6% of the familial responses. The study also portrayed 
poor effectiveness of melatonin usage as the likelihood of any sleep problem persisting 
to subsequent time point increased slightly when compared with those who did not 
receive treatment for their sleep problem (17). 
Clinical trials have been performed as early as in the 1980s. A Japanese study by 
Nomura et al (1985) used a small cohort of girls with RTT. In the study, 5-HTP (n=5), 
L-Dopa (n=4) and DOPS (n=1) were administered to check whether an improved sleep 
was observed or not. Only some improvement in the sleep onset time was observed with 




In 1998, a randomized cross over trial study of Melatonin was performed in a sample of 
nine females with RTT. McArthur and Budden observed that initiation to sleep onset 
was decreased, but no change was found in the frequency of night waking. 
Administration of melatonin seemed to improve total sleep time and sleep efficiency in 
individuals with a worse sleep quality suggesting that individual response to melatonin 
varies and depends on the sleep severity (95).  
An Australian population-based study was conducted in 2014 looking at the treatment 
associated with an improvement of sleep problems in individuals with RTT (17). This is 
the only study to date that used a large cohort (n=320) and the treatment was grouped 
into different categories. The study found that non-specific sleep medications such as 
anti-epileptic drug, risperidone, were commonly used (43.4%); followed by specific 
sleep medications including melatonin, clonidine and chloral hydrate (28.3%); multiple 
treatment types (16.4%); and non -pharmaceutical treatments (12.0%). Out of these, 
melatonin (17.6%) was most commonly used. Anti-epileptic medications (12.5%) and 
variants of benzodiazepine (10.8%) were also used for seizure control.  
Overall, the treatment reduced the risk of any sleep problem by around 1.7%. In 
addition, a decrease in persistent night screaming was witnessed but the treatment had 
little effect on reducing night laughing and less persistent night screaming.  Specifically, 
the report showed that individuals who received specific sleep medications, for example 
melatonin, the chances of any sleep problem persisting to subsequent time point was 
increased in comparison to other individuals who did not receive specific medications 
for their sleep. Also, specific sleep medications seemed to reduce the risk of further 
night laughing and persistent night screaming in the individuals, but no change was 
observed in the occurrence of night screaming (17). However, the study had certain 
limitations. Data on additional sleep problems such as daytime naps and night seizures 
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(81) were missing and in terms of treatment effectiveness, there was a lack of biennial 
observation. 
Limited evidence is provided to show the beneficial outcomes by the use of 
pharmacological strategies as there are few clinical trials performed to demonstrate their 
efficacy. To date, melatonin remains the most assessed sleep medication but studies 
show poor effectiveness by using this type of medication (17, 95). In addition, studies 
should be conducted using controlled trials with large samples to know whether these 
interventions or other methods could improve sleep problems being faced by RTT 
patients.  
1.8.9 Impact of sleep on RTT individuals and families 
 
Sleep problems have an enormous impact on both the affected individual and the 
family, especially on child development and family functioning (96-98). Didden and 
Sigafoos (2001) reviewed the prevalence, correlation and treatment of sleep problems in 
developmentally disabled children and reported problematic daytime sleep behaviour 
was observed in children such as aggression, self-injury and screaming (14).  
The parents of children with sleep dysfunction in association with a developmental 
disability were particularly affected with fatigue, stress and difficulty in coping with 
their parental tasks (71). In addition, parental emotion and cognition are also affected. 
An early study conducted in 1999 focused on the understanding of mothers with an 
infant facing sleep problems. The study measured maternal cognitions in relation to 
infant sleeping problems by using an Infant Sleep Questionnaire (MCISQ). Results 
showed mothers feeling anger and helplessness in response to the infant’s demands and 
feelings of uncertainty about their parenting competence in association with infant sleep 
problems (99). 
In 2005, a qualitative investigation of parental experience with an RTT child was 
performed. In the child, sleep disturbances led to many consequences including mood 
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swings, exhaustion, and lack of energy and increased daytime sleep. The study showed 
how likely disrupted sleep could impact  the health and well-being of both the RTT 
child and family (100).   
Sleep problems not only have an effect on the individual with RTT but on the family as 
well. A qualitative study conducted on nine families with an RTT child mentioned that 
they feel exhausted and it disturbs their own sleep. Four families  described that their 
child’s sleep disturbance has caused an impact on their marital relationship as well as 
social life (100). Emotional impact can also occur in families with regards to parent 
responsibility. Studies reveal that parents feel frustrated and, powerless, and are worried 
about the well-being of their child (100).  
Studies prove that sleep problems causes a huge burden on the RTT child and family 
but the understanding of managing these problems still remains remarkably limited.  
1.9 Significance and gaps in the literature 
 
The literature suggests that individuals with neurodevelopmental disorders are 
particularly vulnerable to sleeping problems, especially those with genetic syndromes 
such as RTT. Whilst most females with RTT develop sleep problems, there is some 
variation with age and mutation but studies still lack the power to provide sufficient 
evidence. In addition, the literature is particularly limited in relation to the evidence 
base for the management of sleep problems. By administering an online questionnaire to 
a large international cohort of families with a daughter with Rett syndrome, the current 
study will investigate specific sleep problems and its relation to the age and mutation 
type and also describe and suggest sleep management techniques that could increase the 
quality of life for a person with RTT and their family.  






The aim of this study is to examine the prevalence, phenotype and management of sleep 
issues in Rett syndrome. 
1.10.2 Objectives 
 
1. Explore the types of sleeping problems observed in females with Rett Syndrome 
and their relationships with age, mutation type and sleep hygiene. 
2. Assessment of sleep disturbances in RTT by looking at the effect of age, 
mutation type, epilepsy, scoliosis and mobility.  
3. Describe specific therapeutic managements for sleep problems and their 




Chapter 2: Methods 
2.1 Study Design 
 




The main infrastructure for this research was the International Rett Syndrome 
Phenotype Database (InterRett) housed at the Telethon Kids Institute and its Consumer 
Reference Group (CRG).  
2.2.1 International Rett Syndrome Database: InterRett 
 
InterRett, an international online database, was established in June 2002 to provide for 
the recruitment of large case numbers to collect and display information about clinical 
characteristics and genotype-phenotype relationships in girls and women with RTT 
(101). The purpose of the database is to disseminate and enhance knowledge about RTT 
for both the general and medical community.  
InterRett has been supported by funding provided from the International Rett Syndrome 
Foundation, now known as Rettsyndrome.org (102). It currently contains data on over 
2500 girls and women with RTT who are resident in one of over 50 countries in the 
world. Following recruitment, families with a child with RTT and clinicians with a 
patient with RTT are asked to contribute data, collected via the submission of web or 
paper based questionnaires administered to both (46, 102). The family questionnaire 
(FQ) was based on materials developed for the Australian Rett Syndrome Database 
(ARSD), a database set up in 1993 to recruit a population-based sample of families with 
a child with RTT born since 1976 and thereafter track their progress longitudinally 
(103). The family questionnaire has been translated into French, Italian, Mandarin, 
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German and Spanish. In addition, de-identified bulk submissions of clinical data from 
Spain, Israel, France and Canada have also been collected (46, 102).  
2.2.2 Consumer Reference Group (CRG) 
 
Originally formed in 2012, the InterRett Consumer Reference Group (CRG) has 
assisted with the development of specific study protocols. More specifically, the CRG 
guides the research methodology, interpretation, implementation and dissemination of 
outcomes of the study (104). The InterRett CRG comprises nine families, mainly 
mothers who have a child with RTT of various ages (children and adults). The CRG 
families had previously been consulted on the overall research questions and were 
consulted again prior to the commencement of this current project on aspects of the 
questionnaire.  




Families already registered with InterRett who were able to speak English were invited 
for the current follow-up study. To date, 380 email invitations have been sent and of 
these, 345 families have returned their questionnaire. Families with a child with Rett 
syndrome of any age were included provided they had a confirmed clinical diagnosis of 
Rett syndrome (42) and/or a pathogenic MECP2 mutation. Families whose daughter had 
passed away were also included if one of their parents had expressed interest in 
participating in the study during routine contacting of already registered families and 






2.3.2 Exclusion of families 
 
Of the 380 families, 345 families had completed and returned the entire questionnaire. 
Of these, 51 families were excluded based on the following criteria: they were reported 
as having a positive result found for MECP2 genetic testing but the mutation type was 
“unknown”, having a “negative” result when tested for a MECP2 mutation or their 
daughters weren’t tested for a MECP2 mutation. Additionally, those families who 
weren’t able to be contacted through Facebook or the details provided in the InterRett 
database were excluded as well.  
2.4 Recruitment and study advertisement 
 
As of mid-December 2014, families who had previously completed the InterRett family 
questionnaire were contacted through telephone to update their contact details and with 
the intention of informing about the upcoming research project in 2015. Later, in early 
2015, between March and 8
th
 May 2015, the InterRett team further contacted the 
families whose child’s pathogenic mutation status was marked in the InterRett database 
as either known/ unknown, in order to discuss the intended research study and to know 
whether they were interested to take part in the project. However, not all families were 
contacted via telephone but also through e-mails too. Families who had not previously 
registered with InterRett were also recruited to first complete the initial family 
questionnaire and then participate in the current study. To achieve both arms of 
recruitment, advertisements were placed on the InterRett Facebook page, the parent 
Listserve RettNet, and the newsletters of parent support associations such as 
Rettsndrome.org in the United States of America and Rett UK in the United 
Kingdom. In June, the study was further promoted at the Reach for Your Stars 2015 
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Virtual Family Conference. In addition, families registered in AussieRett database who 
responded to the above mentioned advertisements were also invited for the current 
study. All participating families in the current study were either sent unique URL 
addresses to the online questionnaire by email or a paper questionnaire by post. 
2.5 Formation of 2015 follow-up questionnaire 
 
2.5.1 Questionnaire consent form 
 
Family members were sent an information sheet and study consent form attached to the 
questionnaire whether it was a web-based or paper version. In the online version, the 
consent form was designed in a way that continuation to the questionnaire required 
completion of the study consent form to ensure that all entered data was usable. 
2.5.2 Process of questionnaire development 
 
The web-based version of questionnaire was developed using REDCap (Research 
Electronic Data Capture). REDCap is a freely available and a secure web application 
that is being increasingly used for building and/or managing online surveys and 
databases especially in the intellectual disability research field. The software contained 
additional features such as providing information regarding the “completion status” of 
each participant, indicated as either incomplete, partial completion or completed. Added 
to that, if a family chose to finish their questionnaire at a later stage once commenced, 
the software would automatically provide a passcode in order to re-access the 
questionnaire as well as for any future references. These specific features finalised on 
making the decision on using this software for the study.  
Two versions of the questionnaire were developed in REDCap: one included questions 
being asked for the type of genetic mutation if this was not previously provided to the 
databases and the other without the genetic mutation questions as the data had already 
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been provided to the databases. Otherwise the two questionnaires were the same. The 
purpose of setting up the questionnaire was to collect information on sleep problems, 
current health and functional status as well as genetic information on the individual with 
Rett syndrome. The questionnaire was structured based on the ARSD 2011 Follow-up 
Study (17), and the family questionnaire for the International CDKL5 Disorder 
Database (105). In addition, two validated sleep measurements tools such as sleep 
disturbances and sleep hygiene questionnaires were incorporated into the questionnaire 
(106, 107). To reduce participant burden, the format of the questionnaire consisted of a 
stem and leaf design where the response to questions would lead to further probing 
questions to investigate the relevant issue. In summary, the questionnaire (Appendix A) 
included the following components: 
 
Data about the child: 
1. Child and family details such as age, mutation type, residential setting, visit to a 
specialist Rett syndrome clinic or not; 
2. Current functional abilities describing variables such as ability to walk, stand, 
sit, hand and language skills; 
3. Current health & wellbeing status looking at comorbidities including epilepsy, 
scoliosis, fractures, gastrointestinal disorders including constipation, reflux and 
abdominal bloating and gallbladder problems, other health issues such as cold 
feet, temperature regulation, osteoporosis, hip dislocation, hip dysplasia and 
unexplained rashes, and feeding patterns; 
4. Use of health services; 





1. Current sleep problems and patterns;  
2. Inclusion of two validated questionnaires on sleep habits and sleep 
disturbances; 
3. Sleep monitoring, sleep supports and assessments; 
4. Use of health services; 
5. Current medications and supplements/ Treatments. 
Data about family wellbeing: 
1. Details regarding who is completing the questionnaire, current parental 
employment status;  
2. Personal health and family quality of life. 
3. In April 2015, a draft questionnaire was sent to the members of the InterRett 
CRG and a teleconference meeting was subsequently held with four of the 
members to review their views and experiences after completing the 
questionnaire. All of their suggested changes including the addition of questions 
in relation to maternal health and family quality of life were later implemented 
into the current questionnaire. 
 
2.5.3 Piloting of the questionnaire  
 
The questionnaire was piloted by the help of the CRG group. In total, four of the ten 
families with a child with RTT, who lived in the United States of America, were part of 
the InterRett Consumer Reference Group, who was consulted prior to piloting the 
questionnaires.  Prior to the meeting, each family was sent the URL link to access the 
online version of the REDCap questionnaire. The intention of sending the link was to 
help the families take note of any errors noticed in the questions or if the wording style 
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of any questions felt uncomfortable, or if any questions needed to be excluded or added 
to the questionnaire and finally to calculate the approximate time taken for each family 
to complete their questionnaire. 
2.5.4 Questionnaire follow-up:  
 
After being sent the questionnaire by email or post, families were telephoned to ensure 
the web link to the REDCap questionnaire or the postal version has been received. 
Families who weren’t able to be contacted by telephone were contacted by e-mail, 
Facebook, text and voice-mail messages. Further, follow up calls were made two weeks 
after the families have confirmed receiving their questionnaire version. Provision of 
questionnaires completion status by REDCap was used as a follow up method to check 
whether any questionnaire was updated or submitted. Further, families were sent a 
thank you message by the means of phone calls or postal letters for their participation.   
 
2.6 Validity and Reliability  
 
The CRG members piloted the prepared questionnaire, all feedback was incorporated 
accordingly and the questionnaire further revised. The questions incorporated for the 
current study have all been previously used successfully with other cohorts and previous 
users have checked the content of these questionnaires. In addition, pre-existing 
validated measures of sleep problems have also been used. 
 New questions were also created in several sections of the study.  In section 8c, sleep 
monitoring, the participants were asked questions related to “smartphone apps”, 
whether the apps have helped to manage their daughter’s sleep and if used which apps 
were they and how useful they were. These questions were written in accordance to the 
principles of a good questionnaire design such as by the use of simple words, avoiding 
33 
 
ambiguous wording, abbreviations or technical terms, optimizing and/or altering the 
length wherever needed, inclusion of ‘don’t know’ or ‘not applicable’ categories where 
appropriate, and further ensuring that any questions relating to recall the memories of 
participants did not fall as a burden.  
2.7 Data collection  
 
This study comprises of ongoing participant reruitment and data collection. However, 
for the purpose of study analyses, families who returned their questionnaires by 9
th
 
September 2015 were included in the sleep analyses. Submission of questionnaires 
thereafter were not accounted for in the analyses.  
2.8 Data analyses 
 
Analysing the sleep data involved the usage of various statistical models. Descriptive 
statistics was used to examine each variable individually. Regression models including 
simple logistic regression and multinomial logistic regression models were employed to 
investigate the relationships between phenotype, treatments and sleep problems.  
 
2.9 Sleep related variables 
 
2.9.1 Types of sleep problems 
 
The parents and/or carers were asked to specify the types of sleep problems their 
daughter experienced including difficulty falling asleep, night laughing, night 
screaming, seizures at night, teeth grinding, night terrors, night waking, daytime 
napping and difficulty waking. The families were given the opportunity to describe 
other sleep problems that were not listed in the questionnaire. Each of these questions 
was answered by choosing one of the six responses: “never”, “has stopped”, “less than 
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once a month”, “monthly”, “twice a month”, “once or more a week”, “nightly”, and 
“more than once a night”. These responses were then collapsed into three categories: 
‘did not occur’ (recorded as ‘never’ or ‘has stopped’), ‘sometimes’ (recorded as ‘less 
than once a month’, ‘monthly’ or ‘twice a month’) or ‘often’ (recorded as ‘once or more 
a week’, ‘nightly’, or ‘more than once a night’).  
Six out of nine sleep problems were used for further sleep analysis: night screaming; 
night waking; difficulty falling asleep; night laughing; daytime napping; and teeth 
grinding. These were selected based on the data in the literature suggesting that these 
were commonly occurring (17, 18). 
From the six sleep problems, only night screaming was measured using simple logistic 
regression while the rest were analysed using multinomial logistic regression. This was 
because there were only a few families reported having night screaming occurred in 
their children as either “sometimes” or “often”, Thus, the outcomes of night screaming 
occurring in RTT cases were reduced to “did not occur” and “ever occurred”, a 
combination of sometimes and often. As night screaming was measured as ever 
occurred, the effect of age was not taken into account as the response indicated a past 
occurrence of screaming through the night.  
The appropriate regression models for each sleep problem produced a univariate 
(Appendix B) and a multivariate outcome upon looking at the effect of age groups, 
mutation types and sleep hygiene scores for the three responses by making “did not 
occur” as the baseline.  
2.9.2 Sleep disturbances Scale 
 
To investigate the occurrence of any sleep disturbances in any RTT individual, the 
Sleep Disturbances Scale for Children was incorporated into the questionnaire, a sleep 
assessment tool extracted from a 1996 validated questionnaire by Bruni et al (106). 
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Twenty-five items were picked out from the twenty-six items of Bruni’s sleep 
disturbances. One item was excluded from the sleep disturbance analysis that asked 
whether an RTT child had “vivid dream-like scenes while falling asleep”. Elimination 
of this one particular item as the study cohort included individuals who were non-verbal 
and with cognitive impairment and so didn’t know whether this item could accurately 
measure sleep disturbances faced by RTT cases. All items were grouped into six 
subscales based on the entities to which they belonged. DIMS (Disorders of Initiating 
and Maintaining Sleep), SBD (Sleep Breathing Disorders), DA (Disorders of Arousal), 
SWTD (Sleep-Wake Transition Disorders), DOES (Disorders Of Excessive 
Somnolence), SHY (Sleep Hyperhidrosis) (Table 1).  





1 Going to bed reluctantly 
2 Difficulty in falling asleep 
3 Falling asleep anxiety 
7 Night awakenings 
8 Difficulty in falling asleep after awakenings 
24 Sleep duration 
25 Sleep latency 
 
SBD 
10 Breathing problems 
11 Sleep apnoea 
12 Snoring 
 14 Sleepwalking 
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4 Hypnic jerks 
5 Rhythmic movement disorders 
9 Nocturnal hyperkinesia 
15 Sleeptalking 




19 Difficulty in waking up 
20 Tired when waking up 
21 Sleep paralysis 
22 Daytime somnolence 
23 Sleep attacks 
SHY 6 Falling asleep sweating 
13 Night sweating 
Table 1: Sleep disturbance factors tested in RTT individuals which was taken from 
Bruni’s study conducted in 1996 (106). 
Unlike Bruni’s measurement of sleep disturbance for children, this study measured 
sleep disturbance of every RTT individual without making any constraints to the age. 
This was done with reference to the latest research that sleep problems persist into 
adulthood and would not diminish with age. Thus, measuring sleep disturbances in 
across various ages helped to find the trend of sleep problems and/or sleep disturbances 
in RTT with relation to age. The twenty-five items were scaled using a “Likert- type 
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rating scale” (106). The responses to the items were categorised: Never, Occasionally, 
Sometimes, Often, and Always.  
The subscale scores were calculated by dividing the total scores attained for each 
subscale by the number of question in each subscale. The total score was calculated by 
taking the sum of the average subscale scores.   
Initially, the total and subscale scores of the Rett syndrome sample were compared with 
the general population. Further, the total sleep score and subscale scores of each 
participant were initially then tested in relation to age groups and mutation types by 
using One-way variance analysis. The total and subscale scores of each participant was 
later analysed using simple regression on the five covariates models (section 2.5.4), 
providing both univariate (listed in Appendix B) and multivariate outcomes.  
Taking into account missing data, families were excluded from the sleep disturbance 
scale analysis if they have missed more than three items to be responded. This was done 
to increase the accuracy of the results and was a methodology extracted from a study 
conducted in 2015 which looked at behavioural problems in Down syndrome (108).  
2.9.3 Sleep hygiene  
 Sleep hygiene, a behavioural strategy used to treat sleep difficulties was incorporated 
into this study to investigate whether it had an effect on specific sleep problems in RTT 
by taking into account the age and genotype of each individual.  A validated 
questionnaire on sleep hygiene was taken out from Malow et al. (2009), a study which 
looked at the sleep habits in children with Autism spectrum disorders (107). Sleep 
hygiene in this study cohort was measured by using a “Likert- type rating scale” and the 
response to the twelve items were categorised as: Never, Occasionally, Sometimes, 
Often, and Always.  
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Not all families responded to all twelve items and some families missed up to three 
items.  In order to increase the result accuracy, the average score of each participant was 
taken into account as their sleep hygiene score. The sleep hygiene average score was 
calculated by dividing the total score by the number of items responded by each 
participant.   
2.9.4 Covariates of sleep problems  
 
Sleeping problems and all other aspects related to sleep problems were compared by 
various factors: 
 Gender: The sleep study included both male and female cases.   
 Age groups:  Age of cases reflected the age when the questionnaire was returned 
upon completion and was grouped as follows: younger than or equal to 7 years of 
age, “0-7 years”; 8 and younger than or equal to 12 years of age, “8-12 years”; 13 
and younger than or equal to 17 years of age, “13-17 years”; and 18 years and over, 
“18 and older”.  
 Classification of MECP2 mutation types:  The genotype of those with a confirmed 
MECP2 mutation were classified into twelve, based on most common mutations in 
RTT individuals (46): Large deletions (LD), C-terminal deletions(CT), early 
truncating (ET), p.Arg106Trp (R106W), p.Arg133Cys (R133C), p.Arg168* 
(R168X), p.Arg255* (R255X), p.Arg270* (R270X), p.Arg294* (R294X), 
p.Arg306Cys (R306C), p.Thr158Met (T158M) and the last group labelled as “other” 
pathogenic  MECP2 mutation types.   
 Epilepsy: In order to find whether the presence of Epilepsy had an effect on the 
sleep problems in RTT cases, the occurrence of seizures were taken into account. 
The outcomes were categorised into four: no seizures currently occurred, 
“No/Completely under control”; “Rarely has a seizure anymore (once or twice per 
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year)”; “Has occasional seizures (once per month)”; “Seizures occur frequently 
(once per week)”; “Seizures are not controlled (daily/more than once a week)”.  
 Scoliosis: Determining whether a spinal curvature do have an impact on the sleep 
problems in RTT cases, the presence of Scoliosis was measured as follows: having 
not diagnosed with Scoliosis, “No”; the curve of the child’s spine, “Mild” or 
“Severe”, having done a spinal fusion, “Surgery”.  
 Mobility: Even if the mobility and the sleep problems in a RTT child do have a 
relation, the current ability of the child to walk was taken into account: Walks with 
no assistance on all surfaces/ Walks with no assistance on level surfaces, “Walks 
with no assistance”; Walks with assistance from a person or walking aid, “Walks 
with assistance”; “Unable to walk”.  
2.9.5 Sleep treatment types 
 
The information on the list of treatments used by individual families on their children to 
reduce any sleep symptoms was taken by looking at section 4 and section 8d of the 
questionnaire. Both sections included questions that were open text style, allowing the 
families to describe the treatment usage in their own style.  The perceived effectiveness 
of the treatments were measured by the question provided in section 8d. The collected 
data on treatments were then analysed by using descriptive statistics.  
2.9.6 Sleep impacts on the child and family 
 
The very last intention by analysing the sleep data was to look at the impacts of sleep 
problems affecting both the family and the child. The data was collected by asking how 
severe was the impact by choosing one of the following responses: none, minor, 
moderate and major. However, the data was analysed by using descriptive statistics in 
the form of binary outcomes: none or minor and moderate or major.   
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2.10 Ethical considerations 
 
For this study, ethics approval was obtained from the ethics committees of The 
University of Western Australia.  
The current study targeted major gaps in the literature and has been indicated as an area 
of interest for Rett families by the InterRett CRG. The InterRett database was used as 
the infrastructure for the study providing a substantial sample size. The researchers were 
extensively experienced with the administration of online questionnaires to families 
with a daughter with Rett syndrome. Thus, the study was able to address the proposed 
research questions.  
Participation in this study was voluntary and participants were free to withdraw from 
the study at any time. An information sheet was provided to participants prior to 
receiving access to a questionnaire and the study was discussed over the telephone with 
the family members. Opportunity to provide consent form was included in the 
questionnaire for participant convenience. Completion of the ‘yes’ checkbox on this 
form by participants was accepted as the informed consent. This strategy enabled the 
collection of informed consent with minimal burden to families.    
Each participant was given a unique study identification number that was then later used 
in all analyses. Returned data were converted to a password protected database stored 
on a secure network within the Telethon Kids Institute. Only authorized study personnel 
had access to this data. No named or identifiable data was included in any subsequent 
publications or presentations.  
Families were able to retain a copy of the completed questionnaire as a valuable tool in 
tracking their child’s health status. It was not anticipated that participants will suffer any 
adverse effects from participation in this study because the nature of the questionnaire 
was not expected to produce any discomfort or distress. As usual practice, the 
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information sheet directed family members to contact Dr Helen Leonard over any 
concerns that may arise upon completion of the questionnaire. Some participants were 
inconvenienced by the time taken to complete the questionnaire. However, this 
participant burden was resolved by only asking questions directly involved with the 
objectives of the project and utilizing a ‘save & return’ function for the convenience of 






Chapter 3: Results 




 September 2015, 380 families had been invited to participate in the follow-up 
questionnaire and 345 families (89% response fraction) had provided data. The majority 
of families completed the web based questionnaire (n=283) with the remainder 
completing a postal version (n=11). Analysis was restricted to the 294 cases (85%) with 
a delineated pathogenic MECP2 mutation. The cohort represented seven different 
nationalities as illustrated in Figure 1. The majority of individuals with Rett syndrome 
lived at their parental home (n=277, 94.5%) and 11 individuals (3.8%) lived in group 
home or community residential settings. The majority of respondents were the natural 
mother (n=266, 90%), approximately one third of whom worked as a full-time 
homemaker (37.2%) and another one third worked full-time (34.8%).  
All but two cases were female. The distribution of MECP2 mutation types is shown in 
Table 1. The mean age at questionnaire completion ranged from 2.1 to 57.2 years with a 
median age of 14.1 years.   
Figure 1: Distribution of various ethnic groups representing the study cohort (n=294). 
















Slightly fewer than one third of cases were aged between 8-12 years (n=90, 30.6%), 
while a smaller proportion were aged 0-7 years (n=45, 15.3%) (Table 1). The frequency 
distribution for the 11 MECP2 mutation groups is provided in Table 1.  
Data on epilepsy were provided for 290 out of 294 individuals. Of those, 131 (45.2%) 
had no or completely controlled seizures, a smaller proportion (10.7%, n=31) 
experienced seizures rarely whereas 44 (15.2%) had occasional seizures and 44 (15.2%) 
frequent seizures (Table 1) while 40 individuals had uncontrolled seizures (13.8%) . 
Data on scoliosis were reported for 283 out of 294 individuals. A small proportion 
(9.5%, n=27) were reported as having a severe scoliosis, nearly one third (32.5%, n=92) 
had a mild spinal curvature while a further third (32.5%, n=92) had no scoliosis.  
Additionally a quarter (25.4%, n=72) had undergone a spinal fusion (Table 1). 
Over one third were able to walk with no assistance (117, 39.8%), a little over one 
quarter were able to walk with assistance (81, 27.6%) and the remaining one third (96, 
32.7%) were unable to walk (Table 1). 
Sleep hygiene scores ranged from 2.08 to 4.17. A mean score of 3.26 (SD 0.35) 






Table 1: Distribution of characteristics of the study sample (n=294). 
  N (%) 
Age group  
(years) 
0-7 45 (15.3%) 
8-12  90 (30.6%) 
13-17  74 (25.2%) 
18 and older 85 (28.9%) 
Mutation types 
 
Large deletion 21 (7.1%) 
C terminal deletion 32 (10.9%) 
Early truncating 17 (5.8%) 
p.Arg106Trp 14 (4.7%) 
p.Arg133Cys 22 (7.5%) 
p.Arg168* 27 (9.2%) 
p.Arg255* 31 (10.5%) 
p.Arg270* 21 (7.1%) 
p.Arg294* 25 (8.5%) 
p.Arg306Cys 23 (7.8%) 
p.Thr158Met 26 (8.8%) 




No seizures or completely under control 131 (45.2%) 
Rarely has a seizure any more (once or 
twice per year) 
31 (10.7%) 
Has occasional seizures (once per month) 44 (15.2%) 
Seizures occur frequently (once per week) 44 (15.2%) 
Seizures are not controlled (daily/more 





No 92 (32.5%) 
Mild 92 (32.5%) 
Severe 27 (9.5%) 
Surgery 72 (25.4%) 
Mobility  
Walks with no assistance  117 (39.8%) 






a: total sample=290 due to some missing data. 
b: total sample=283 due to some missing data. 
c: score out of five and calculated by taking the average of the total score divided by the number of 
questions responded by each participant, with higher scores representing more use of sleep hygiene 
strategies. 
‘*’ represents the stop codons of the related genotypes  
  
Unable to walk 96 (32.7%) 
  Mean (SD) 





3.2 Specific sleep problems of Rett syndrome 
 
Night waking was the most prevalent sleep problem with slightly more than half 
(50.5%, n=146) waking at night often and slightly more than one quarter (25.6%, n=75) 
waking at night sometimes. A smaller proportion (18%) had never experienced night 
waking and 5.9% had previously experienced night waking but this had now stopped 
(Table 2). Additionally, difficulty falling asleep had been reported for 59.8%, night 
laughing for 58.4% and teeth grinding for 46% of individuals. Night terrors and night 
screaming were less common (Table 2). 
Table 2: Occurrence and frequency of specific sleep problems observed in girls and 
















52 (18.0) 17  (5.9) 74    (25.6) 146   (50.5) 289 
Night laughing 
 




78 (26.8) 39  (13.4) 82    (28.2) 92     (31.6) 291 




Seizures at night 
 
127 (44.3) 54  (18.8) 74    (25.8) 32     (11.2) 287 
Night screaming 
 
154 (52.9) 62  (21.3) 47    (16.2) 28     (9.6) 291 
Daytime napping 
 
160 (54.8) 26  (8.9) 67    (23.0) 39      (13.4) 292 
Night terrors 
 
179 (60.9) 53  (18.0) 45    (15.3) 17     (5.8) 294 
Difficulty waking 
 
184 (64.18) 11  (3.8) 58    (20.2) 34      (11.9) 287 
a 
Denominator varies for each sleep problem due to some missing data 
b Categorisation of three responses into one group: “Less than once a month”, “Monthly” and “Twice a 
month”  
c Categorisation of three responses into one group: “Once or more a week”, “Nightly” and “More than 








3.3 Relationships between specific sleep problems, age, genotype and use of 
sleep hygiene strategies. 
 
Univariate effects of each covariate in relation to the six specific sleep problems are 
shown in Tables 3, 5, 7,9 ,11 and 13 (Appendix B) and multivariate relationships are 
presented below.  
3.3.1 Night screaming  
 
Taking into account the effect of mutation type, the likelihood of night screaming was 
highest for individuals with p.Arg294* mutation type (OR 4.29, 95%CI 0.99, 18.59). 
Individuals with C-terminal deletion [OR 2.73 (0.65, 11.43)] also had increased odds of 
night screaming. In contrast, individuals with p.Arg106Trp [0.5 (0.05, 5.39)] genotype 
were less likely to have experienced night screaming (Model 1, Table 4).  
3.3.1.1 Relationship with genotype and sleep hygiene score 
 
Upon analysing the effect of two covariates together, similar findings were observed. 
Considering the effect of sleep hygiene, individuals with p.Arg294* mutation type had 
increased odds of night screaming having ever occurred (OR 4.05, 95%CI 0.86, 
19.01). Individuals with the genotypes p.Arg133Cys [2.28 (0.47, 11.00)] and C-
terminal deletion [2.28 (0.52, 10.04)] also had increased odds of ever experiencing 
night screaming. Any occurrence of night screaming were less likely to happen in 
individuals who had p.Arg106Trp [0.33 (0.03, 3.80)] and p.Arg270* [0.81 (0.14, 
4.52)] genotypes (Model 2, Table 4). 
Furthermore, taking into account the effect of genotype, night screaming was less likely 
to occur in those who practiced sleep hygiene in their daily lives (OR 0.02, 95%CI 1.23, 
6.42). (Model 2, Table 4). 
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Table 4: Univariate (Model 1) and multivariate analyses (Model 2) of the relationships between occurrence of night screaming, mutation type and use of sleep hygiene strategies 
(n=291). 
                                                     




  Model 1a Model 2b 
 n (%)  ORc 
(95% CId) 
p value ORc 
(95% CId) 
p value 
Mutation type       
Large deletion 18 (8.3) 3 (4.0) baseline baseline baseline baseline 
C terminal deletion 22 (10.2) 10 (13.3) 2.73 (0.65,11.43) 0.170 2.28 (0.52,10.04) 0.277 
Early truncating 14 (6.5) 3 (4.0) 1.29 (0.22,7.37) 0.778 1.32 (0.22,7.92) 0.762 
p.Arg106Trp 12 (5.6) 1 (1.3) 0.5 (0.05,5.39) 0.568 0.33 (0.03,3.80) 0.376 
p.Arg133Cys 15 (6.9) 7 (9.3) 2.8 (0.61,12.75) 0.183 2.28 (0.47,11.00) 0.303 
p.Arg168* 20 (9.2) 7 (9.3) 2.1 (0.47,9.36) 0.331 1.53 (0.32,7.29) 0.594 
p.Arg255* 23 (10.6) 8 (10.7) 2.09 (0.48,9.02) 0.324 1.54 (0.33,7.18) 0.581 
p.Arg270* 17 (7.5) 4 (5.3) 1.41 (0.27,7.26) 0.680 0.81 (0.14,4.52) 0.806 
p.Arg294* 14 (6.5) 10 (13.3) 4.29 (0.99,18.59) 0.052 4.05 (0.86,19.01) 0.077 
p.Arg306Cys 17 (7.9) 6 (8.0) 2.12 (0.46,9.84) 0.338 1.29 (0.26,6.50) 0.757 
p.Thr158Met 19 (8.8) 7 (9.3) 2.21 (0.49,9.89) 0.299 1.42 (0.29,6.88) 0.660 
Other 25 (11.6) 9 (12.0) 2.16 (0.51,9.12) 0.295 1.90 (0.42,8.68) 0.405 





a Model 1-logistic effects of mutation type                                                                                                                
b Model 2-logistic effects of mutation type and sleep hygiene score 
c 
OR, odds ratio  
d 
CI, confidence interval 
e calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes   
Total scoree (n=292) - - - - 0.02 (1.23,6.42) 0.014 
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3.3.2 Night waking 
 
The relationship between night-waking, age group and genotype is shown in Table 6 
(Model 1). After adjusting for genotype, the occurrence of frequent night waking was 
higher in those aged 8-12 years (OR 1.54, 95%CI 0.60, 3.94) and those aged 18 years 
and above [OR 1.91 (0.75, 4.90)]. There were also increased odds of frequent night 
waking in individuals with p.Arg133Cys mutations [OR 2.20 (0.32, 14.86)]. However, 
reduced odds [0.24 (0.04, 1.40)] of frequent night waking were reported for those with a 
p.Arg306Cys mutation.  When sleep hygiene was included in the model (Model 2) the 
odds of frequent night waking were increased by 1.56 times (95% CI 0.65, 3.74) for 
each unit increase of the sleep hygiene score (Table 6). 
3.3.3 Difficulty falling asleep 
 
The relationship between sleep initiation, age group and genotype is shown in Table 8 
(Model 1). Those in the youngest age group had most difficulty in falling asleep when 
adjusted for genotype.  When adjusted for age group, the odds of having frequent 
difficulty falling asleep were increased for those with the p.Arg294* mutation (OR 4.20, 
95%CI 0.99, 17.84). However, reduced odds [0.52 (0.08, 3.57)] of difficulty falling 
asleep often were reported for those with a p.Arg106Trp mutation.  When sleep hygiene 
was included in the model (Model 2) the odds of difficulty in falling asleep were 
increased by 1.91 times (95% CI 0.83, 4.40) for each unit increase of the sleep hygiene 
score (Table 8). 
3.3.4 Night laughing 
 
The relationship between night laughing, age group and genotype is shown in Table 10 
(Model 1). As with sleep initiation those in the youngest age group had the highest odds 
of night laughing when adjusted for genotype.  When adjusted for age group, the odds 
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of night laughing frequently were increased for those with a p.Arg270*(OR 14.80, 
95%CI 1.18, 155.41), p.Arg133Cys [12.44 (1.20, 132.79)] and p.Arg294* [10.05 (1.12, 
107.87)] mutation and lowest in those with a p.Arg306Cys mutation [1.60 (0.11, 
21.46)]. The inclusion of sleep hygiene in the model (Model 2) considerably increased 
the risk of night laughing [2.64 (95% CI 0.96, 7.29)] (Table 10). 
3.3.5 Daytime napping 
 
The relationship between daytime napping, age group and genotype is shown in Table 
12 (Model 1). The odds of frequent occurrence of daytime napping were highest in the 
13-17 year age group (OR 3.15, 95%CI (0.87, 11.37) and lowest in those aged 0-7 years 
when adjusted for genotype.  When adjusted for age group, the odds of frequent 
daytime napping were higher in those with the p.Arg168* [OR 3.52 (0.71, 17.56)], 
p.Arg294* [OR 3.28 (0.63, 17.07)] and p.Arg270*[OR 3.26 (0.60, 17.83)] mutations 
and lowest in those with a p.Arg255* mutation [OR 0.26 (0.02, 2.80)]. The inclusion of 
sleep hygiene in the model (Model 2) increased the risk of daytime napping by 1.38 
times (95% CI 0.49, 3.89) (Table 12). 
3.3.6 Teeth grinding 
 
The relationship between teeth grinding at night and age group and genotype is shown 
in Table 14 (Model 1). As with sleep initiation and night laughing, those in the youngest 
age group had the highest odds of teeth grinding when adjusted for genotype.  When 
adjusted for age group, the odds of frequent teeth-grinding were highest in those with a 
p.Arg133Cys mutation (OR 2.10, 95%CI 0.52, 8.77) and lowest in those with a 
p.Arg106Trp mutation [0.27 (0.04, 1.74)]. The inclusion of sleep hygiene in the model 




Table 6: Multivariate analyses of the relationships between occurrence of night waking, age group, mutation type and use of sleep hygiene strategies (n=289). 
 
a Model 1-Multivariate effects of age and mutation type                                                                                                                                                                                                               
b Model 2- Multivariate effects of age, mutation type and sleep hygiene score 
c OR, odds ratio 
d CI, confidence interval 
e calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes  
 Did not 
occur 
(n=69) 
Sometimes (n=74) Often (n=146) 
  Model 1a Model 2b Model 1a Model 2b 
 n (%) n (%) ORc (95% CId) p value ORc (95% CId) p value n (%) ORc (95% CId) p value ORc (95% CId) p value 
Age group            
0-7 years 13 (18.8) 12 (16.2) baseline baseline baseline baseline 19 (13.0) baseline baseline baseline baseline 
8-12  years 19 (27.5) 24 (32.3) 1.37 (0.48,3.91) 0.553 1.37 (0.48,3.93) 0.549 45 (30.8) 1.54 (0.60,3.94) 0.364 1.50 (0.58,3.84) 0.400 
13-17  years 21 (30.4) 17 (23.0) 0.93 (0.32,2.72) 0.900 0.94 (0.32,2.74) 0.908 35 (24.0) 1.14 (0.45,2.91) 0.786 1.14 (0.44,2.91) 0.791 
18 and older 16 (23.2) 21 (28.4) 1.57 (0.55,4.52) 0.401 1.55(0.54,4.46) 0.415 47 (32.2) 1.91 (0.75,4.90) 0.176 1.95 (0.76,5.01) 0.163 
Mutation type            
Large deletion 4 (5.8) 6 (8.1) baseline baseline baseline baseline 11 (7.5) baseline baseline baseline baseline 
C terminal deletion 7 (13.5) 7 (9.4) 0.66 (0.12,3.49) 0.624 0.66 (0.12,3.47) 0.619 18 (12.3) 0.92 (0.21,3.99) 0.916 0.93 (0.21,4.02) 0.922 
Early truncating 6 (8.7) 6 (8.1) 0.68 (0.12,3.80) 0.662 0.68 (0.12,3.79) 0.660 5 (3.4) 0.30 (0.06,1.60) 0.159 0.30 (0.06,1.60) 0.159 
p.Arg106Trp 4 (5.8) 2 (2.7) 0.31 (0.04,2.72) 0.293 0.32 (0.04,2.78) 0.301 8 (5.5) 0.61 (0.12,3.66) 0.642 0.62 (0.11,3.43) 0.584 
p.Arg133Cys 2 (2.9) 5 (6.8) 1.70 (0.21,13.91) 0.618 1.69 (0.21,13.81) 0.623 12 (8.2) 2.20 (0.32,14.86) 0.417 2.14 (0.32,14.44) 0.436 
p.Arg168* 4 (5.8) 6 (8.1) 0.98 (0.16,6.11) 0.985 0.97 (0.16,6.06) 0.977 16 (11.0) 1.44 (0.29,7.27) 0.659 1.45 (0.29,7.34) 0.654 
p.Arg255* 11 (15.9) 8 (10.8) 0.50 (0.10,2.49) 0.399 0.50 (0.10,2.47) 0.395 12 (8.2) 0.41 (0.10,1.75) 0.231 0.42 (0.10,1.77) 0.234 
p.Arg270* 3 (4.3) 5 (6.8) 1.08 (0.15,7.62) 0.937 1.10 (0.16,7.76) 0.924 13 (8.9) 1.54 (0.27,8.75) 0.624 1.45 (0.25,8.25) 0.679 
p.Arg294* 6 (8.7) 2 (2.7) 0.22 (0.03,1.75) 0.152 0.22 (0.03,1.76) 0.154 16 (11.0) 0.94 (0.21,4.29) 0.941 0.98 (0.21,4.47) 0.977 
p.Arg306Cys 6 (8.7) 13 (17.6) 1.43 (0.28,7.41) 0.667 1.44 (0.28,7.45) 0.663 4 (2.7) 0.24 (0.04,1.40) 0.114 0.24 (0.04,1.35) 0.105 
p.Thr158Met 7 (13.5) 4 (5.4) 0.38 (0.06,2.30) 0.291 0.38 (0.06,2.30) 0.289 15 (10.3) 0.78 (0.17,3.49) 0.745 0.75 (0.17,3.39) 0.714 
Other 9 (13.0) 10 (13.5) 0.82 (0.17,4.08) 0.810 0.81 (0.16,4.01) 0.796 16 (11.0) 0.72 (0.17,3.04) 0.650 0.72 (0.17,3.07) 0.658 
Sleep hygiene            
Total scoree - - - - 0.90  (0.34,2.41) 0.832 - - - 1.56  (0.65,3.74) 0.315 
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Table 8: Multivariate analyses of frequency of difficulties falling asleep in relation to age group, mutation type and use of sleep hygiene strategies (n=291). 
 
a Model 1-Multivariate effects of age and mutation type                                                                                                                                                                                                                                                                                                                                                                                                                                                              
b Model 2- Multivariate effects of age, mutation type and sleep hygiene score 
c 
OR, odds ratio 
d 
CI, confidence interval 
e calculated by taking the average of the total score divided by the number of questions responded by each participant  
‘*’ represents the stop codons of the related genotypes  




Often  (n=92) 
 Model 1a Model 2b Model 1a Model 2b 
n (%) n (%) ORc (95% CId) p value ORc (95% CId) p value n (%) ORc (95% CId) p value ORc (95% CId) p value 
Age group            
0-7 years 10 
(8.5%) 
16 (19.5) 
baseline baseline baseline baseline 
18 (19.6) 
baseline baseline baseline baselin
e 
8-12  years 39 (33.3) 20 (24.4) 0.31(0.11,0.86) 0.025 0.32(0.11,0.87) 0.026 30 (32.6) 0.47 (0.18,1.21) 0.117 0.45 (0.17,1.17) 0.099 
13-17  years 35 (29.9) 21 (25.6) 0.37 (0.14,1.02) 0.056 0.37 (0.14,1.03) 0.057 18 (19.6) 0.27(0.10,0.75) 0.012 0.27(0.10,0.74) 0.011 
18 and older 33 (28.2) 25 (30.5) 0.45 (0.17,1.22) 0.116 0.45 (0.17,1.21) 0.114 26 (28.3) 0.43 (0.16,1.12) 0.083 0.43(0.16,1.14) 0.090 
Mutation type            
Large deletion 
11 (9.4) 5 (6.1) 
baseline baseline baseline baseline 
5 (5.4) 
baseline baseline baseline baselin
e 
C terminal deletion 14 (12.0) 7 (8.5) 0.89(0.21,3.68) 0.872 0.89(0.21,3.68) 0.869 11 (12.0) 1.58(0.41,6.09) 0.504 1.62(0.42,6.30) 0.483 
Early truncating 8 (6.8) 6 (7.3) 1.51(0.33,6.85) 0.593 1.52(0.33,6.87) 0.589 3 (3.3) 0.89(0.16,4.96) 0.898 0.91(0.16,5.09) 0.912 
p.Arg106Trp 8 (6.8) 4 (4.9) 0.87(0.17,4.52) 0.868 0.88(0.17,4.63) 0.884 2 (2.2) 0.52(0.08,3.57) 0.510 0.48(0.07,3.31) 0.459 
p.Arg133Cys 8 (6.8) 6 (7.3) 1.32(0.29,6.08) 0.719 1.33(0.29,6.12) 0.712 8 (8.7) 2.07(0.47,9.01) 0.333 2.07(0.47,9.08) 0.335 
p.Arg168* 6 (5.1) 15 (18.3) 4.21(0.98,18.03) 0.053 4.21(0.98,18.07) 0.053 6 (6.6) 1.91(0.39,9.31) 0.422 1.95(0.40,9.55) 0.410 
p.Arg255* 17 (14.5) 6 (7.3) 0.57(0.13,2.43) 0.446 0.57(0.13,2.44) 0.450 7 (7.6) 0.79(0.19,3.26) 0.742 0.81(0.19,3.40) 0.778 
p.Arg270* 8 (6.8) 7 (8.5) 1.42(0.31,6.47) 0.644 1.46(0.32,6.65) 0.623 6 (6.6) 1.40(0.30,6.55) 0.663 1.29(0.27,6.11) 0.746 
p.Arg294* 7 (6.0) 4 (4.9) 1.02(0.20,5.36) 0.979 1.02(0.19,5.34) 0.985 13 (14.1) 4.20(0.99,17.84) 0.052 4.46(1.03,19.32) 0.045 
p.Arg306Cys 9 (7.7) 7 (8.5) 1.20(0.27,5.36) 0.811 1.21(0.27,5.39) 0.807 6 (6.6) 1.16(0.25,5.33) 0.846 1.13(0.24,5.22) 0.878 
p.Thr158Met 9 (7.7) 4 (4.9) 0.70(0.14,3.58) 0.670 0.71(0.14,3.62) 0.679 13 (17.4) 2.67(0.65,10.86) 0.171 2.63(0.64,10.78) 0.180 
Other 12 (10.2 11 (13.4) 1.53(0.38,6.09) 0.546 1.52(0.38,6.07) 0.549 12 (13.0) 2.15(0.54,8.51) 0.277 2.23(0.56,8.92) 0.257 
Sleep hygiene            
Total score - - - - 0.92 (0.39,2.19) 0.726 - - - 1.91(0.83,4.40) 0.129 
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 Table 10: Multivariate analyses of night laughing in relation to age group, mutation type and use of sleep hygiene strategies (n=293). 
   a Model 1-Multivariate effects of  age and mutation type                                                                                                                                                                                                       
   b Model 2- Multivariate effects of age, mutation type and sleep hygiene score 
   
c 
OR, odds ratio  
    d 
CI, confidence interval 
  e calculated by taking the average of the total score divided by the number of questions responded by each participant 
 ‘*’ represents the stop codons of the related genotypes  





 Model 1a Model 2b Model 1a Model 2b 
n (%) n (%) ORc (95% CId) p value ORc (95% CId) p value n (%) ORc (95% CId) p value ORc (95% CId) p value 
Age group            
0-7 years 10 (8.2) 21 (17.6) baseline baselin
e 
baseline baseline 14 (26.9) baseline baselin
e 
baseline baseline 
8-12  years 34 (27.9) 39 (32.8) 0.59 (0.23,1.48) 0.256 0.57 (0.23,1.44) 0.235 16 (30.8) 0.37 (0.11,1.00) 0.067 0.34 (0.11,1.00) 0.051 
13-17  years 34 (27.9) 29 (24.4) 0.45 (0.18,1.15) 0.096 0.45 (0.17,1.15) 0.096 12 (23.1) 0.20 (0.06,0.61) 0.005 0.19 (0.06,0.61) 0.005 
18 and older 44 (36.1) 30 (25.2) 0.34 (0.14,0.85) 0.021 0.34 (0.14,0.85) 0.021 10 (19.2) 0.13 (0.04,0.40) 0.000 0.13 (0.04,0.40) 0.000 
Mutation type            
Large deletion 11 (9.0) 9 (7.6) baseline baselin
e 
baseline baseline 1 (1.9) baseline baselin
e 
baseline baseline 
C terminal deletion 10 (8.2) 16 (13.4) 2.12 (0.64,7.12) 0.223 2.13 (0.64,7.17) 0.220 6 (11.5) 7.16 (0.74,77.71) 0.096 7.57 (0.74,77.71) 0.088 
Early truncating 9 (7.4%) 6 (5.0 0.94 (0.24,3.70) 0.924 0.94 (0.24,3.71) 0.925 2 (3.8) 3.18 (0.25, 45.05) 0.379 3.38 (0.25, 45.05) 0.357 
p.Arg106Trp 8 (6.6) 4 (3.4) 0.75 (0.16,3.45) 0.707 0.72 (0.15,3.34) 0.673 2 (3.8) 3.74 (0.24,47.50) 0.324 3.41 (0.24,47.50) 0.362 
p.Arg133Cys 7 (5.7) 8 (6.7) 1.54 (0.39,6.09) 0.534 1.54 (0.39,6.08) 0.537 7 (13.5) 12.44 (1.20,132.79) 0.035 12.61 (1.20,132.79) 0.035 
p.Arg168* 10 (8.2) 15 (12.6) 1.97 (0.57,6.76) 0.283 1.98 (0.57,6.81) 0.280 2 (3.8) 2.23 (0.17,31.55) 0.544 2.32 (0.17,31.55) 0.527 
p.Arg255* 13 (10.6) 15 (12.6) 1.43 (0.44,4.71) 0.557 1.44 (0.44,4.74) 0.552 3 (5.8) 2.34 (0.21,28.87) 0.498 2.44 (0.21,28.87) 0.480 
p.Arg270* 5 (4.1) 10 (8.4) 2.75 (0.66,11.54) 0.166 2.68 (0.64,11.26) 0.178 6 (11.5) 14.80 (1.18,155.41) 0.029 13.56 (1.18,155.41) 0.036 
p.Arg294* 13 (10.6) 3 (2.5%) 0.33 (0.07,1.59) 0.169 0.34 (0.07,1.62) 0.175 9 (17.3) 10.05 (1.12,107.87) 0.046 10.99 (1.12,107.87) 0.040 
p.Arg306Cys 11 (9.0) 9 (7.6) 0.95 (0.26,3.47) 0.940 0.94 (0.26,3.43) 0.926 2 (3.8) 1.60 (0.11,21.46) 0.723 1.57 (0.11,21.46) 0.736 
p.Thr158Met 12 (9.8) 9 (7.6) 0.96 (0.27,3.44) 0.944 0.95 (0.26,3.41) 0.932 5 (9.6) 4.37 (0.40,45.67) 0.221 4.26 (0.40,45.67) 0.232 
Other 13 (10.6) 15 (12.6) 1.50 (0.45,4.95) 0.510 1.50 (0.45,4.99) 0.505 7 (13.5) 6.15 (0.64,66.13) 0.122 6.52 (0.64,66.13) 0.113 
Sleep hygiene            
Total scoree - - - - 1.24 (0.57,2.71) 0.576 - - - 2.64 (0.96,7.29) 0.061 
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Table 12: Multivariate analyses of diurnal problems in relation to age group, mutation type and use of sleep hygiene strategies (n=292).                                                                                   
a Model 1-Multivariate effects of age and mutation type                                                                                                                                                                                                               
b Model 2- Multivariate effects of age, mutation type and sleep hygiene score 
c 
OR, odds ratio 
d 
CI, confidence interval 
e calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes
 Did not 
occur 
(n=186) 
Sometimes (n=67) Often (n=39) 
 
 Model 1a Model 2b Model 1a Model 2b 
 n (%) n (%) ORc 
 (95% CId) 
p value ORc  
(95% CId) 
p value n (%) ORc 
 (95% CId) 
p value ORc (95% CId) p value 
Age group            
0-7 years 29 (15.6) 12 (17.9) baseline baseline baseline baseline 4 (10.2) baseline baseline baseline baseline 
8-12  years 56 (30.1) 21 (31.3) 0.95 (0.39,2.32) 0.922 0.94 (0.39,2.29) 0.892 12 (30.8) 2.00 (0.55,7.24) 0.290 1.95 (0.54,7.10) 0.309 
13-17  years 46 (24.7) 14 (20.9) 0.81 (0.31,2.08) 0.655 0.81 (0.31,2.08) 0.659 14 (35.9) 3.15 (0.87,11.37) 0.080 3.14 (0.87,11.36) 0.081 
18 and older 55 (29.6) 20 (29.8) 0.87 (0.37,2.10) 0.764 0.89 (0.37,2.13) 0.785 9 (23.1) 1.26 (0.34,4.66) 0.732 1.28 (0.34,4.75) 0.714 
Mutation type            
Large deletion 14 (7.5) 4 (6.0) baseline baseline baseline baseline 3 (7.7) baseline baseline baseline baseline 
C terminal deletion 24 (12.9) 6 (9.0) 0.88 (0.21,3.73) 0.862 0.89 (0.21,3.77) 0.869 2 (5.1) 0.47 (0.07,3.19) 0.437 0.46 (0.07,3.19) 0.435 
Early truncating 13 (7.0) 4 (6.0) 1.12 (0.23,5.52) 0.887 1.13 (0.23,5.56) 0.883 0 (0.0) - 0.985 - 0.985 
p.Arg106Trp 13 (7.0) 1 (1.5) 0.28 (0.03,2.89) 0.283 0.26 (0.03,2.77) 0.268 0 (0.0) - 0.987 - 0.987 
p.Arg133Cys  15 (8.1) 6 (9.0) 1.42 (0.32,6.25) 0.644 1.41 (0.32,6.22) 0.650 1 (2.6) 0.36 (0.03,3.96) 0.404 0.35 (0.03,3.88) 0.392 
 
p.Arg168* 13 (7.0) 6 (9.0) 1.61 (0.35,7.34) 0.537 1.62 (0.36,7.41) 0.531 7 (17.9) 3.52 (0.71,17.56) 0.125 3.50 (0.70,17.50) 0.126 
p.Arg255* 22 (11.8) 8 (11.9) 1.28 (0.31,5.24) 0.732 1.29 (0.31,5.30) 0.723 1 ((2.6) 0.26 (0.02,2.80) 0.265 0.26 (0.02,2.81) 0.266 
p.Arg270* 10 (5.4) 6 (9.0) 2.09 (0.45,9.79) 0.348 2.01 (0.43,9.44) 0.379 5 (12.8) 3.26 (0.60,17.83) 0.173 3.11 (0.57,17.11) 0.191 




0.112 6 (15.4) 3.28 (0.63,17.07) 0.159 3.33 (0.64,17.37) 0.153 
p.Arg306Cys 14 (7.5) 7 (10.4) 1.73 (0.40,7.54) 00.468 1.71 (0.39,7.45) 0.478 2 (5.1) 0.92 (0.13,6.65) 0.937 0.91 (0.13,6.56) 0.926 
p.Thr158Met 14 (7.5) 5 (7.5) 1.24 (0.26,5.83) 0.787 1.23 (0.26,5.78) 0.797 6 (15.4) 2.78 (0.53,14.12) 0.217 2.71 (0.53,13.81) 0.231 
Other 24 (12.9) 5 (7.5) 0.75 (0.17,3.39) 0.706 0.76 (0.17,3.44) 0.720 6 (15.4) 1.28 (0.26,6.25) 0.762 1.27 (0.26,6.24) 0.767 
Sleep hygiene            
Total scoree - - - - 1.34 (0.58,3.12) 0.492 - - - 1.38 (0.49,3.89) 0.547 
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Table 14: Multivariate analyses of teeth grinding in relation to age group, mutation type and use of sleep hygiene strategies (n=291). 
a Model 1-Multivariate effects of age and mutation type    
 b Model 2- Multivariate effects of age, mutation type and sleep hygiene score 
 c 
OR, odds ratio 
d 
CI, confidence interval 
e calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes  




Sometimes (n=58) Often (n=76) 
 Model 1a Model 2b Model 1a Model 2b 




p value ORc 
 (95% CId) 
p value n (%) ORc  
(95% CId) 
p value ORc  
(95% CId) 
p value 
Age groups            
0-7 years 19 8 baseline baseline baseline baseline 18 baseline baseline baseline baseline 
8-12  years 51 20 1.07 (0.39,2.99) 0.892 1.08 (0.39,3.02) 0.878 18 0.32 (0.13,0.78) 0.013 0.32 (0.13,0.80) 0.014 
13-17  years 38 16 1.0 (0.35,2.88) 0.991 1.01 (0.35,2.89) 0.988 18 0.41 (0.16,1.04) 0.062 0.41 (0.16,1.04) 0.061 
18 and older 49 14 0.8 (0.30,2.41) 0.752 0.84 (0.29,2.40) 0.740 22 0.41 (0.17,0.98) 0.046 0.41 (0.17,0.98) 0.044 
Mutation types            
Large deletion 11 4 baseline baseline baseline baseline 6 baseline baseline baseline baseline 
C terminal deletion 19 8 1.23 (0.29,5.14) 0.777 1.23 (0.29,5.13) 0.781 5 0.38 (0.09,1.61) 0.191 0.38 (0.09,1.60) 0.188 
Early truncating 9 3 0.97 (0.17,5.55) 0.969 0.96 (0.17,5.52) 0.962 4 0.75 (0.16,3.58) 0.721 0.75 (0.16,3.55) 0.714 
p.Arg106Trp 11 0 0 0.985  0.985 2 0.27 (0.04,1.74) 0.168 0.28 (0.04,1.81) 0.181 
p.Arg133Cys 7 4 1.67 (0.31,9.10) 0.553 1.68 (0.31,9.17) 0.548 10 2.1 (0.52,8.77) 0.297 2.15 (0.52,8.90) 0.289 
p.Arg168* 13 5 1.15 (0.24,5.52) 0.865 1.14 (0.24,5.50) 0.868 9 0.96 (0.25,3.74) 0.952 0.95 (0.24,3.72) 0.945 
p.Arg255* 18 9 1.47 (0.35,6.15) 0.599 1.46 (0.35,6.12) 0.604 4 0.28 (0.06,1.29) 0.103 0.28 (0.06,1.29) 0.103 
p.Arg270* 11 4 1.09 (0.21,5.67) 0.921 1.11 (0.21,5.82) 0.900 6 0.74 (0.17,3.21) 0.691 0.78 (0.18,3.37) 0.734 
p.Arg294* 14 1 0.21 (0.02,2.22) 0.196 0.21 (0.02,2.21) 0.194 10 1.09 (0.29,4.09) 0.899 1.08 (0.29,4.05) 0.914 
p.Arg306Cys 15 3 0.59 (0.11,3.28) 0.547 0.59 (0.11,3.31) 0.552 5 0.42 (0.09,1.85) 0.250 0.42 (0.10,1.87) 0.255 
p.Thr158Met 12 4 0.99 (0.19,5.12) 0.992 1.00 (0.19,5.17) 0.999 10 1.11 (0.29,4.31) 0.882 1.13 (0.29,4.39) 0.862 
Other 17 13 2.24 (0.55,9.07) 0.259 2.22 (0.55,9.01) 0.263 5 0.38 (0.09,1.63) 0.191 0.37 (0.09,1.61) 0.187 
Sleep hygiene            
Total scoree     0.85 (0.34,2.11) 0.721    0.76 (0.33,1.75)   0.522 
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3.4 Comparison of sleep disturbance scales with the study cohort and normative 
sample 
 
The mean of total sleep disturbance score measured by the Sleep Disturbances Scale for 
Children (106) was higher in the study cohort [10.10 (SD 2.75)] than in the normative 
sample [7.98 (SD 1.28)] (106). Looking at the six subscale factors, the means of DIMS 
[1.95 (SD 0.73)], SBD [1.76 (SD 0.87)], DA [1.21 (SD 0.38)], SWTD [1.95 (SD 0.76)] 
and DOES [1.91 (SD 0.77)] were all higher in the Rett syndrome sample than in the 
normative sample (106). However, the mean of SHY [1.44 (SD 0.85)] was lower in the 
Rett syndrome sample compared to the normative sample.  
Table 15: Comparing the Mean (SD) sleep disturbance total and subscale average scores.  
 
                                                             Sleep disturbance scale 
 Our cohort
a 








































1.32 (0.71) 1.44 (0.85) 0.018 
  a Sample with Rett syndrome  (n=267) 
 b Sample from general population (106) 
 c 
calculated by adding up the average of the six subscale scores (DIMS average+ SBD average+ DA 
average+ SWTD average+ DOES average+ SHY average) 
d DIMS-Disorders of initiating and maintaining sleep 
e SBD- Sleep breathing disorders 
f DA- Disorders of arousal 
g SWTD- Sleep-wake transition disorders 
h DOES- Disorders of excessive somnolence 






3.5 Relationships of age and genotype with total sleep disturbance scores  
 
The mean total sleep disturbance score was highest in children less than seven years of 
age [11.23 (SD 2.90)]. In contrast, individuals aged 18 and above had the lowest mean 
total sleep scores [9.54 (SD 2.55)]. The total sleep disturbance scores were different 
among the four age groups (F (3, 263) = 3.46, P = 0.017) (Figure 2).  
Individuals with p.Arg 294* genotype (11.30 (SD 3.75)] had the highest mean of total 
sleep disturbance scores. Individuals with the p.Arg133Cys genotype [10.09 (SD 2.30)], 
p.Arg270* [10.13 (SD 2.53)], p.Thr158Met [10.78 (SD 3.28)] and the “other” genotype 
category also had high means total sleep scores. In contrast, individuals who had an 
early truncating genotype had lowest total sleep score with a mean of 9.39 (SD 2.36). 
The total sleep disturbance scores were not different among the mutation types (F (11, 





         Figure 2: Mean (SD) total sleep disturbance scores in relation to age groups (n=267).  
                                    
 






















Age groups (years) 
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Figure 3: Mean (SD) total sleep disturbance scores in relation to mutation type (n=267).                                                                                                                              
 
























3.6 Impacts of age, genotype, epilepsy, scoliosis and mobility on total sleep 
disturbance scores 
 
Univariate effects of all five covariates are shown in Tables 16, (in the Appendices) and 
multivariate relationships are presented below. 
In the multivariate model 1, the total sleep disturbance scores were lower in individuals 
in the older age groups (8-12 years: -1.33 (95% CI -2.40,-0.26); 13-17 years: -1.14   
(95% CI -2.28,-0.00); 18+ years: -1.69 (95% CI -2.76,-0.63) when compared with those 
in the youngest age group. Using large deletion as the reference level, the total score 
was relatively higher in individuals with p.Arg294* (1.63; 95% CI -0.07, 3.33) 
mutation. Similarly, individuals with uncontrolled seizures had a higher total score 
(1.56; 95% CI 0.53, 2.58) than those with no history of epilepsy or controlled seizure. 
When scoliosis and mobility were added into the model (Model 2), the total sleep 
disturbance scores in those with mild or severe scoliosis or ever had fusion surgery were 
similar to those never diagnosed with scoliosis. Being unable to walk or walking with 
assistance appeared to be negatively associated with sleep quality, as reflected by the 
slight increase in the total score (0.79; 95% CI -0.26, 1.84 and 0.72; 95% CI -0.22, 1.67 
respectively) when compared to being able to walk unaided (Table 17). 
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a calculated by adding up the average of the six subscale scores (DIMS average+ SBD average+ DA average+ SWTD average+ DOES average+ SHY average) 
b CI, confidence interval  
‘*’ represents the stop codons of the related genotypes  
 
Covariates 
Total sleep scorea 
Model 1 (n=264) Model 2 (n=253) 
n Coefficient (95% CIb) p value n Coefficient (95%  CIb ) p value 
Age groups 
0-7 years 39 baseline - 38 baseline - 
8-12  years 86 -1.33 (-2.40,-0.26) 0.015 85 -1.03 (-2.20,0.13) 0.083 
13-17  years 63 -1.14  (-2.28,-0.00) 0.049 60 -0.86  (-2.19,0.48) 0.209 
18 and older 76 -1.69 (-2.76,-0.63) 0.002 70 -1.17  (2.46,0.12) 0.076 
Mutation types 
Large deletion 19 baseline - 19 baseline - 
C terminal deletion 28 -0.15 (-1.74,1.43) 0.848 26 -0.30 (-1.94,1.34) 0.717 
Early truncating 16 -0.36 (-2.17,1.46) 0.699 15 -0.26 (-2.14,1.61) 0.782 
p.Arg106Trp 13 0.21(-1.75,2.17) 0.836 13 0.10 (-1.90,2.10) 0.920 
p.Arg133Cys 19 0.56 (-1.19,2.31) 0.530 17 0.47 (-1.39,2.32) 0.621 
p.Arg168* 24 0.09 (-1.56,1.75) 0.911 24 -0.09 (-1.79,1.62) 0.918 
p.Arg255* 27 -0.31(-1.93,1.30) 0.703 25 -0.66 (-2.36,1.04) 0.443 
p.Arg270* 19 0.35 (-1.40,2.11) 0.694 18 0.20 (-1.65,2.05) 0.831 
p.Arg294* 22 1.63 (-0.07,3.33) 0.060 22 1.64 (-0.14,3.41) 0.070 
p.Arg306Cys 21 -0.28 (-2.01,1.44) 0.747 21 -0.33 (-2.08,1.43)  0.716 
p.Thr158Met 22 0.95 (-0.73,2.65) 0.265 20 0.69 (-1.10,2.49) 0.447 
Other 34 0.74 (-0.82,2.31) 0.350 33 0.57 (-1.04,2.18) 0.484 
Epilepsy 
No/ completely under control 117 baseline - 116 baseline - 
Rarely has a seizure any more (once or twice per year) 30 0.88 (-0.23,2.00) 0.120 30 0.79 (-0.36,1.94) 0.179 
Has occasional seizures (once per month) 40 -0.06 (-1.05,0.94) 0.910 36 -0.08 (-1.13,0.98) 0.888 
Seizures occur frequently (once per week) 40 -0.03 (-1.04,0.98) 0.959 37 -0.16 (-1.24,0.92) 0.774 
Seizures are not controlled (daily/more than once a week) 37 1.56 (0.53,2.58) 0.003 34 1.13 (0.01,2.25) 0.048 
Scoliosis 
No - - -  84                  baseline - 
Mild - - - 84          -0.30 (-1.23,0.64) 0.536 
Severe - - - 26 0.04 (-1.32,1.40) 0.951 
Surgery - - - 59 -0.63 (-1.91,0.64) 0.329 
Mobility 
Walks with no assistance  - - - 104                baseline - 
Walks with assistance  - - - 71 0.72 (-0.22,1.67) 0.134 
Unable to walk - - - 78 0.79 (-0.26,1.84) 0.139 
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3.7 Differences of sleep disturbance subscale average scores in relation to age 
and genotype 
 
The mean DIMS subscale score was highest in children less than seven years of age 
[2.06 (SD 0.77)]. While, individuals who aged between eight and 12 had the lowest 
mean DIMS score [1.88 (SD 0.71)]. There was no significant effect of DIMS score on 
any age group (F (3, 263) = 0.73, P = 0.533) (Figure 4). Taking the effect of mutation 
types into account, individuals with p.Arg 294* genotype [2.51 (SD 0.93)] had the 
highest mean DIMS score. In contrast, individuals who had an early truncating 
genotype had lowest DIMS score with a mean of 1.67 (SD 0.56). The mean DIMS 
subscale scores were different among the mutation types (F (11, 255) = 2.73, P = 0.002) 
(Figure 5a).   
The mean SWTD subscale score was highest in children who aged less than seven years 
[2.39 (SD 0.77)]. While, individuals who were eighteen years and older had the lowest 
mean SWTD score [1.76 (SD 0.74)]. There was a significant effect of SWTD score on 
the age groups (F (3, 263) = 6.51, P = 0.0003) (Figure 4). Taking the effect of mutation 
types into account, individuals who had p.Arg133Cys genotype [2.34 (SD 0.90)] had 
the highest mean SWTD score. In contrast, individuals who had p.Arg106Trp genotype 
had lowest SWTD score with a mean of 1.62 (SD 0.72). The mean SWTD subscale 
scores were not different among the mutation types (F (11, 255) = 1.27, P = 0.245) 
(Figure 5a).   
The mean DOES subscale score was highest in children less than seven years of age 
[2.06 (SD 0.75)]. While, individuals who were eighteen years of age and older had the 
lowest mean DOES score [1.76 (SD 0.73)].There was no significant effect of DOES 
score on any age group (F (3, 263) = 1.61, P = 0.188) (Figure 4). Taking the effect of 
mutation types into account, individuals with p.Arg 294* genotype [2.1 (SD 0.88)] had 
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the highest mean DOES score. In contrast, individuals who had an early truncating 
genotype had lowest DOES score with a mean of 1.63 (SD 0.47). The mean DOES 
subscale scores were different among the mutation types (F (11, 255) = 2.73, P = 0.002) 
(Figure 5a).   
The mean SBD subscale score was highest in children less than seven years of age [1.98 
(SD 0.99)]. While, individuals who were between eight and 12 years of age, had the 
lowest mean SBD score [1.69 (SD 0.71)]. There was no significant effect of SBD score 
on any age group (F (3, 263) = 1.04, P = 0.375) (Figure 4). Taking the effect of 
mutation types into account, individuals with other genotype [2.10 (SD 1.06)] had the 
highest mean SBD scores. In contrast, individuals who had a c-terminal deletion 
genotype had lowest sleep score with a mean of 1.5 (SD 0.76). The mean SBD subscale 
scores were not different among the mutation types (F (11, 255) = 0.99, P = 0.452) 
(Figure 5b).   
The mean SHY subscale score was highest in children between thirteen and 17 years of 
age [1.43 (SD 0.89)]. While, individuals who were eighteen years of age and older had 
the lowest mean SHY score [1.24 (SD 0.61)].There was no significant effect of SHY 
score on any age group (F (3, 263) = 1.01, P = 0.391) (Figure 4). Taking the effect of 
mutation types into account, individuals with p.Arg 106Trp genotype [1.54 (SD 0.75)] 
had the highest mean of SHY score. In contrast, individuals who had p.Arg306Cys had 
sleep score with a mean of 1.19 (SD 0.33). The mean SHY subscale scores were 
different among the mutation types (F (11, 255) = 0.51, P = 0.897) (Figure 5b).   
The mean DA subscale score was highest in children less than seven years of age [1.37 
(SD 0.46)]. While, individuals who were eighteen years of age and above had the lowest 
mean SHY score [1.12 (SD 0.27)].There was a significant effect of DA score on the age 
groups (F (3, 263) = 3.89, P = 0.010) (Figure 4). Taking the effect of mutation types 
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into account, individuals with p.Arg 294* genotype [1.28 (SD 0.47)] had the highest 
mean of DA scores. In contrast, individuals who had p.Arg106Trp genotype had lowest 
sleep score with a mean of 1.62(SD 0.72). The mean DA subscale scores were not 




Figure 4: Mean (SD) sleep disturbance subscale average scores in relation to age group.  






































DIMS-Disorders of initiating and maintaining sleep 
SBD- Sleep breathing disorders 
DA- Disorders of arousal 
SWTD- Sleep-wake transition disorders 
DOES- Disorders of excessive somnolence 




Figure 5a: Mean (SD) sleep disturbance subscale average scores of Disorders of initiating and maintaining sleep (DIMS),  Sleep-wake transition disorders (SWTD), 














































Figure 5b: Mean (SD) sleep disturbance subscale average scores of Sleep breathing disorders (SBD), Sleep hyperhydrosis (SHY), and Disorders of arousal (DA) in 












































3.8 Impact of age, genotype, epilepsy, scoliosis and mobility in relation to the 
subscale: DIMS 
 
All covariates were individually analysed and these univariate effects are displayed in 
Table 18 (In the Appendices). Multivariate relationships are presented below.  
In the multivariate model 1, the average DIMS sleep disturbance score was lower in 
individuals in the older age groups (8-12 years: -0.15 (95% CI -0.43, 0.14); 13-17 years: 
-0.06 (95% CI -0.36, 0.24); 18+ years: -0.11 (95% CI -0.39, 0.17) when compared with 
those in the youngest age group. Using the large deletion as the reference level, the 
average score was slightly higher in individuals with p.Arg294* genotype (0.75; 95% 
CI 0.30, 1.20). The average score in those who had rare seizures (0.36; 95% CI 0.07, 
0.66) were slightly higher when compared to those whose seizures were controlled or 
had no history of epilepsy. When scoliosis and mobility were added into the model 
(Model 2), the average sleep disturbance score in those with mild or severe scoliosis or 
ever had fusion surgery were similar to those who were never diagnosed with scoliosis. 
Not able to walk or walking with assistance appeared to be positively associated with 
sleep quality, as reflected by the slight decrease in the average score (-0.15; 95% CI -
0.42, 0.13 and -0.04; 95% CI -0.28, 0.21 respectively) when compared to being able to 
walk unaided (Table 19). 
3.9 Impact of age, genotype, epilepsy, scoliosis and mobility in relation to the 
subscale: SWTD 
 
All covariates were individually analysed and these univariate effects are displayed in 
Table 18 (In the Appendices). Multivariate relationships are presented below.  
In the multivariate model 1, the average SWTD sleep disturbance score was lower in 
individuals in the older age groups (8-12 years: -0.43 (95% CI -0.72,-0.13); 13-17 years: 
-0.52 (95% CI -0.83,-0.21); 18+ years: -0.62 (95% CI -0.91,-0.32) when compared with 
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those in the youngest age group. Using the large deletion as the reference level, the 
average score was slightly higher in individuals with p.Arg133Cys genotype (0.35; 95% 
CI -0.13, 0.83). Individuals with uncontrolled seizures had a slightly higher score (0.05; 
95% CI -0.23, 0.33) than those with no history of epilepsy or controlled seizure. When 
scoliosis and mobility were added into the model (Model 2), the average sleep 
disturbance score in those with mild or severe scoliosis or who had fusion surgery were 
very similar to those who were never diagnosed with scoliosis. Not being able to walk 
or walking with assistance appeared to be positively associated with sleep quality, as 
reflected by the slight decrease in the average score (-0.13; 95% CI -0.41, 0.16 and -0.8; 
95% CI -0.34, 0.18 respectively) when compared to being able to walk unaided (Table 
20). 
3.10 Impact of age, genotype, epilepsy, scoliosis and mobility in relation to the 
subscale: DOES 
 
All covariates were individually analysed and these univariate effects are displayed in 
Table 18 (In the Appendices). Multivariate relationships are presented below.  
In the multivariate model 1, the average DOES sleep disturbance score was lower in 
individuals in the older age groups (8-12 years: -0.21 (95% CI -0.49, 0.08); 13-17 years: 
-0.17 (95% CI -0.47, 0.14); 18+ years: -0.29 (95% CI -0.58,-0.01) when compared with 
those in the youngest age group. Using the large deletion as the reference level, the 
average score was slightly lower in individuals with p.Arg255* genotype (-0.32; 95% 
CI -0.81, 0.17). The average score in those who had uncontrolled seizures (0.83; 95% 
CI 0.55, 1.11) and occasional seizures (0.28; 95% CI 0.01, 0.55) were higher when 
compared to those whose seizure were controlled or had no history of epilepsy.  When 
scoliosis and mobility were added into the model (Model 2), the average sleep 
disturbance score in those with mild or severe scoliosis or who had fusion surgery were 
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very similar to those who were never diagnosed with scoliosis. Not being able to walk 
or walking with assistance appeared to be negatively associated with sleep quality, as 
reflected by the slight increase in the average score (0.37; 95% CI 0.09, 0.65 and 0.25; 













Model 1 (n=264) Model 2 (n=267) 
n Coefficient (95%  CIa) p value n Coefficient (95%  CIa) p value 
Age groups 
0-7 years 39 baseline - 38 baseline - 
8-12  years 86 -0.15 (-0.43,0.14) 0.308 85 -0.17 (-0.48,0.13) 0.261 
13-17  years 63 -0.06 (-0.36,0.24) 0.682 60 -0.08 (-0.43,0.26) 0.636 
18 and older 76 -0.11 (-0.39,0.17) 0.447 70 -0.11 (-0.45,0.23) 0.514 
Mutation types 
Large deletion 19 baseline - 19 baseline - 
C terminal deletion 28 0.02 (-0.40,0.43) 0.938 26 -0.00 (-0.43,0.43) 0.999 
Early truncating 16 -0.11 (-0.59,0.37) 0.651 15 -0.12 (-0.61,0.37) 0.631 
p.Arg106Trp 13 0.12 (-0.40,0.63) 0.659 13 0.12 (-0.40,0.64) 0.656 
p.Arg133Cys 19 0.12 (-0.34,0.58) 0.607 17 0.02 (-0.47,0.50) 0.941 
p.Arg168* 24 0.03 (-0.41,0.46) 0.898 24 0.07 (-0.37,0.52) 0.744 
p.Arg255* 27 -0.05 (-0.48,0.37) 0.815 25 0.00 (-0.44,0.45) 0.988 
p.Arg270* 19 0.11 (-0.35,0.57) 0.631 18 0.19 (-0.29,0.67) 0.431 
p.Arg294* 22 0.75 (0.30,1.20) 0.001 22 0.73 (0.27,1.19) 0.002 
p.Arg306Cys 21 0.15 (-0.30,0.61) 0.514 21 0.13 (-0.33,0.59) 0.585 
p.Thr158Met 22 0.56 (0.12,1.00) 0.013 20 0.55 (-0.08,1.01) 0.022 
Other 34 0.26 (-0.15,0.67) 0.219 33 0.22 (-0.20,0.64) 0.302 
Epilepsy 
No/ completely under control 117 baseline - 116 baseline - 
Rarely has a seizure any more (once or twice per year) 30 0.36 (0.07,0.66) 0.016 30 0.36 (0.06,0.66) 0.019 
Has occasional seizures (once per month) 40 -0.11 (-0.38,0.15) 0.393 36 -0.14 (-0.42,0.13) 0.314 
Seizures occur frequently (once per week) 40 -0.02 (-0.29,0.24) 0.857 37 -0.03 (-0.32,0.25) 0.807 
Seizures are not controlled (daily/more than once a week) 37 0.15 (-0.12,0.42) 0.275 34 0.15 (-0.14,0.45) 0.303 
Scoliosis 
No - - - 84 baseline - 
Mild - - - 84 0.05 (-0.20,0.29) 0.715 
Severe - - - 26 0.04 (-0.31,0.40) 0.804 
Surgery - - - 59 -0.01(-0.34,0.32) 0.958 
Mobility 
Walks with no assistance  - - - 104 baseline - 
Walks with assistance  - - - 71 -0.04 (-0.28,0.21) 0.771 
Unable to walk - - - 78 -0.15 (-0.42,0.13) 0.294 
a CI, confidence interval 
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 Table 20: Multivariate analyses of sleep disturbance subscale average scores: Sleep breathing disorders (SWTD). 
 






Model 1 (n=264) Model 2 (n=267) 
n Coefficient (95%  CIa) p value n Coefficient (95%  CIa) p value 
Age groups 
0-7 years 39 - - 38 - - 
8-12  years 86 -0.43 (-0.72,-0.13) 0.005 85 -0.42 (-0.73,-0.10) 0.010 
13-17  years 63 -0.52 (-0.83,-0.21) 0.001 60 -0.48 (-0.84,-0.12) 0.010 
18 and older 76 -0.62 (-0.91,-0.32) 0.000 70 -0.50 (-0.85,-0.15) 0.006 
Mutation types 
Large deletion 19 - - 19 - - 
C terminal deletion 28 -0.04 (-0.47,0.40) 0.874 26 -0.13 (-0.58,0.31) 0.553 
Early truncating 16 -0.01 (-0.51,0.49) 0.974 15 0.05 (-0.46,0.56) 0.849 
p.Arg106Trp 13 -0.31 (-0.85,0.23) 0.264 13 -0.29 (-0.83,0.25) 0.294 
p.Arg133Cys 19 0.35 (-0.13,0.83) 0.152 17 0.18 (-0.32,0.68) 0.480 
p.Arg168* 24 -0.20 (-0.66,0.25) 0.381 24 -0.16 (-0.63,0.30) 0.489 
p.Arg255* 27 -0.29 (-0.74,0.15) 0.197 25 -0.28 (-0.74,0.18) 0.236 
p.Arg270* 19 -0.18 (-0.67,0.30) 0.452 18 -0.15 (-0.65,0.35) 0.556 
p.Arg294* 22 0.21 (-0.25,0.68) 0.367 22 0.15 (-0.33,0.63) 0.550 
p.Arg306Cys 21 -0.16 (-0.64,0.31) 0.502 21 -0.20 (-0.68,0.28) 0.405 
p.Thr158Met 22 0.12 (-0.35,0.58) 0.613 20 0.09 (-0.40,0.58) 0.711 
Other 34 -0.02 (-0.45,0.41) 0.923 33 -0.02 (-0.46,0.42) 0.928 
Epilepsy 
No/ completely under control 117 - - 116 - - 
Rarely has a seizure any more (once or twice per year) 30 -0.16(-0.47,0.14) 0.295 30 -0.15 (-0.47,0.16) 0.334 
Has occasional seizures (once per month) 40 -0.18 (-0.46,0.09) 0.189 36 -0.22 (-0.51,0.06) 0.125 
Seizures occur frequently (once per week) 40 -0.18 (-0.46,0.09) 0.195 37 -0.14 (-0.43,0.16) 0.358 
Seizures are not controlled (daily/more than once a week) 37 0.05 (-0.23,0.33) 0.739 34 0.06 (-0.24,0.36) 0.700 
Scoliosis 
No - - - 84 - - 
Mild - - - 84 -0.08 (-0.34,0.17) 0.534 
Severe - - - 26 0.12 (-0.25,0.49) 0.531 
Surgery - - - 59 -0.17 (-0.51,0.18) 0.346 
Mobility 
Walks with no assistance  - - - 104 - - 
Walks with assistance  - - - 71 -0.8 (-0.34,0.18) 0.533 
Unable to walk - - - 78 -0.13 (-0.41,0.16) 0.384 
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Model 1 (n=264) Model 2 (n=267) 
n Coefficient (95%  CIa) p value n Coefficient (95%  CIa) p value 
Age groups 
0-7 years 39 - - 38 - - 
8-12  years 86 -0.21 (-0.49,0.08) 0.161 85 -0.11 (-0.42,0.20) 0.486 
13-17  years 63 -0.17 (-0.47,0.14) 0.286 60 -0.07 (-0.42,0.29) 0.714 
18 and older 76 -0.29 (-0.58,-0.01) 0.045 70 -0.16 (-0.50,0.18) 0.357 
Mutation types 
Large deletion 19 - - 19 - - 
C terminal deletion 28 0.12 (-0.31,0.54) 0.594 26 0.11 (-0.33,0.54) 0.630 
Early truncating 16 -0.32 (-0.81,0.17) 0.199 15 -0.31 (-0.81,0.19) 0.228 
p.Arg106Trp 13 -0.18(-0.71,0.35) 0.507 13 -0.23 (-0.76,0.30) 0.395 
p.Arg133Cys 19 -0.13 (-0.60,0.34) 0.595 17 -0.01 (-0.50,0.49) 0.982 
p.Arg168* 24 0.08 (-0.36,0.53) 0.721 24 -0.01 (-0.46,0.44) 0.968 
p.Arg255* 27 -0.24 (-0.68,0.19) 0.274 25 -0.35 (-0.80,0.10) 0.124 
p.Arg270* 19 0.17 (-0.30,0.65) 0.472 18 0.12 (-0.37,0.61) 0.630 
p.Arg294* 22 0.21 (-0.24,0.67) 0.357 22 0.25 (-0.22,0.72) 0.292 
p.Arg306Cys 21 -0.20 (-0.67,0.26) 0.396 21 -0.18 (-0.65,0.28) 0.438 
p.Thr158Met 22 0.06 (-0.39,0.52) 0.791 20 -0.03 (-0.50,0.45) 0.911 
Other 34 0.11 (-0.31,0.54) 0.593 33 0.07 (-0.35,0.50) 0.740 
Epilepsy 
No/ completely under control 117 - - 116 - - 
Rarely has a seizure any more (once or twice per year) 30 0.25 (-0.05,0.55) 0.105 30 0.21 (-0.09,0.52) 0.168 
Has occasional seizures (once per month) 40 0.28 (0.01,0.55) 0.042 36 0.33 (0.05,0.61) 0.020 
Seizures occur frequently (once per week) 40 0.19 (-0.08,0.46) 0.177 37 0.11 (-0.18,0.39) 0.463 
Seizures are not controlled (daily/more than once a week) 37 0.83 (0.55,1.11) 0.000 34 0.68 (0.38,0.98) 0.000 
Scoliosis 
No - - - 84 - - 
Mild - - - 84 -0.02 (-0.27,0.22) 0.847 
Severe - - - 26 -0.05 (-0.42,0.31) 0.766 
Surgery - - - 59 -0.12 (-0.46,0.22) 0.488 
Mobility 
Walks with no assistance  - - - 104 - - 
Walks with assistance  - - - 71 0.25 (-0.00,0.50) 0.050 
Unable to walk - - - 78 0.37 (0.09,0.65) 0.010 
a CI, confidence interval 
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3.11 Perceived effectiveness of sleep specific medication and non-medication 
types  
 
Of 292 families, 164 families monitored their child’s sleep (56.2%) and of 294 families, 
127 have used sleep supports for their child. Out of 127 families, a weighted blanket 
was commonly used (n=47, 16%), and pulse oximetry (n=26, 8.8%) and supplemental 
oxygen (n=20, 6.8%) were also used. Two families used the EMFIT seizure/movement 
monitor to monitor sleep for their child (0.7%). 
In total, 115 individuals received either non-pharmacological and/or pharmacological 
medication. The majority (84.62%, n=44) of parents reported that non-pharmaceutical 
interventions such as weighted blanket, standing fan, hot showers, warm milk, relaxing 
music, usage of gel mattress, sound machine, graduated foam mattress on top of an air 
mattress, essential oils, wedge pillow, gluten and dairy free diet, white noise-stand-
alone fan, ceiling fan, daily exercise and lavender scented candles were effective in 
reducing their children’s sleeping problems with only 3.8% (n=2) reporting that 
sleeping problems had worsened (Figure 6).  
Different treatment outcomes were observed in those treated with pharmacological 
medications. In the study cohort, thirteen different types of medications were reported to 
be used. Melatonin was the most commonly used (n=49). It was reported by 71.4% of 
parents as effective but with no beneficial effect for 14 individuals (28.6%). The second 
most commonly used medication was Clonidine, reported to be effective in 79.2% but 
with no positive effect in five (20.8%) individuals. Trazodone appeared to have an 
improved effect for seventeen individuals (85%) although there was no reported effect 
for three individuals (15%). Other medications used included Diazepam (n=4), 
Risperidone (n=2), and Hypnotic (n=2) and each were reported to have beneficial 
effects (Figure 6). 
77 
 
Figure 6: Different treatment types for poor sleep and their perceived effectiveness in individuals with Rett syndrome. 
 
 






























3.12 Impact of sleep on both the Rett syndrome child and their family 
 
In the multivariate model, the moderate or major sleep impact in a child with Rett 
syndrome was higher in individuals in the older age groups (8-12 years: 0.841 (95% CI 
0.388, 1.821); 13-17 years: 0.832 (95% CI 0.373, 1.858); 18+ years: 0.855 (95% CI 
0.399, 1.832) when compared with those in the youngest age group. Using the large 
deletion as the reference level, the sleep impact on the child was slightly higher in 
individuals with p.Arg294* genotype (1.898; 95% CI 0.562, 6.404). The sleep impact 
was also higher in individuals with p.Arg270* (1.419; 95% CI 0.403, 4.997), 
p.Arg106Trp (1.194; 95% CI 0.292, 4.886) and p.Thr158Met genotypes (1.032; 95% CI 
0.303, 3.512). However, the impact was reported to be lower for those with an early 
truncating genotype (0.348; 95% CI 0.075, 1.616) (Table 23). 
In the multivariate model, the moderate or major sleep impact on families with a child 
with Rett syndrome was highest in individuals who were aged between 13 to 17 years of 
age (1.175 (95% CI 0.541,2.553). The sleep impact was also higher in 8-12 (0.714; 95% 
CI 0.337, 1.515) and 18+ years age groups (0.931; 95% CI 0.443, 1.957) when 
compared with those in the youngest age group. Using the large deletion as the 
reference level, the sleep impact on the family was higher in individuals with p.Arg294* 
genotype (1.773; 95% CI 0.530, 5.926). However, the impact was reported to be lower 
for those families with a child who had an early truncating genotype (0.363; 95% CI 






Table 23: Multivariate analyses of sleep impacts in individuals with Rett syndrome and their family. 
 Sleep impact on the child 
(n=291) 
Sleep impact on the family 
(n=292) 
None or Minor Moderate or Major None or Minor Moderate or Major 
Age groups n (%) n (%) ORa (95% CIb) p value n (%) n (%) ORa (95% CIb) p value 
0-7 26  (14.4) 18   (16.4) baseline baseline 23  (14.7) 22  (16.3) baseline baseline 
8-12 56 (30.9) 33   (30.0) 0.841 (0.388,1.821) 0.660 54  (34.4) 36  (26.7) 0.714 (0.337,1.515) 0.380 
13-17 47 (25.9) 26   (23.6) 0.832 (0.373,1.858) 0.655 36 (22.9) 37  (27.4) 1.175 (0.541,2.553) 0.683 
18 and older 52  (28.7) 33   (30.0) 0.855 (0.399,1.832) 0.687 44  (28.0) 40  (29.6) 0.931 (0.443,1.957) 0.850 
Mutation types - -  - - -  - 
Large deletion 13  (7.2) 8     (7.3) baseline baseline 12  (7.6) 9    (6.7) baseline baseline 
C terminal deletion 20  (11.1) 12   (10.9) 0.941 (0.300,3.003) 0.930 17  (10.8)  15  (11.1) 1.098 (0.355,3.401) 0.871 
Early truncating 14  (7.7) 3     (2.7) 0.348 (0.075,1.616) 0.178 13  (8.3) 4    (3.0) 0.363 (0.086,1.525) 0.166 
p.Arg106Trp 8    (4.4) 6     (5.5) 1.194 (0.292,4.886) 0.805 7    (4.5) 7    (5.2) 1.201 (0.297,4.839) 0.798 
p.Arg133Cys 14  (7.7) 8     (7.3) 0.903 (0.257,3.168) 0.873 10  (6.4) 12  (8.9) 1.455 (0.426,4.967) 0.549 
p.Arg168* 16  (8.8) 10   (9.1) 0.975 (0.289,3.289) 0.968 16  (10.2) 11  (8.2) 0.847 (0.257,2.785) 0.784 
p.Arg255* 21  (11.6) 10   (9.1) 0.741 (0.226,2.429) 0.620 18  (11.5) 12  (8.9) 0.789 (0.246,2.528) 0.690 
p.Arg270* 11  (6.1) 10   (9.1) 1.419 (0.403,4.997) 0.585 10  (6.4) 11  (8.2) 1.357 (0.388,4.739) 0.633 
p.Arg294* 11  (6.1) 13   (11.8) 1.898 (0.562,6.404) 0.302 10  (6.4)  15  (11.1) 1.773 (0.530,5.926) 0.353 
p.Arg306Cys 14  (7.7) 9     (8.2) 0.992 (0.285,3.452) 0.990 11  (7.0) 12  (8.9) 1.349 (0.396,4.594) 0.632 
p.Thr158Met 15  (8.3) 10   (9.1) 1.032 (0.303,3.512) 0.960 13  (8.3) 12  (8.9) 1.137 (0.340,3.799) 0.834 
Other 24  (13.3) 11   (10.0) 0.718 (0.223,2.308) 0.578 20  (12.7)  15  (11.1) 0.836 (0.270,2.593) 0.757 
 
a
OR, odds ratio 
b 
CI, confidence interval









Chapter 4: Discussion 
 
4.1 Summary of key findings 
 
Sleep problems in Rett syndrome are more pronounced than in the general population. 
This study investigated various RTT specific sleep problems in relation to factors such 
as age and mutation type and described various management strategies in a large 
international study cohort by administering a follow-up questionnaire. It was found that 
night waking occurred most commonly across the cohort with daytime napping and 
night screaming occurring less frequently. The prevalence of most sleep problems were 
highest in young children and in those with a p.Arg294* mutation. Regression analyses 
further showed that severe epilepsy was associated with poorer sleep, taking into 
account the effects of age, mutation type and mobility. Non-pharmacological 
interventions were perceived as generally effective. However, usage of sleep hygiene 
generally appeared to have little effect on sleep problems although their use appeared 
protective against night screaming. Further, poor sleep had considerable impacts on the 
child and family, particularly for older children and those with a p.Arg294* mutation 
type. 
4.2 Specific Rett syndrome sleep symptoms 
 
Impaired sleep patterns are one among the supportive criteria used when making a Rett 
syndrome diagnosis (42). Early literature since 1986 has reported sleep dysfunction in 
individuals with Rett syndrome (31, 42, 109, 110). However, studies conducted more 
recently have looked at the presence and prevalence of sleep problems in Rett syndrome 
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by using a large cohort that is population-based (17, 18, 81). This current study found 
that the prevalence of sleep problems was high in more than three quarters of the study 
sample and is consistent with the findings of two large population based studies 
conducted in 2007 and 2014 which both found also that sleep problems occurred in 
more than 80% of their samples (17, 18).   
Additionally, the sleep problems found in this study are reported in two recent 
population based studies conducted in 2007 and 2014 using a large cohort sample like 
ours (5, 6). Our findings show that amongst six specific sleep problems, night waking 
was most prevalent. Parents reported that more than half of the individuals often 
experienced night waking more than any other sleep problems, consistent also with the 
findings of Wong et al (2014) where night waking often occurred in around 55% of 
their sample. Our findings further depicted that difficulties falling asleep and night 
laughing (17, 18) were also highly prevalent in approximately 60% of the individuals 
with RTT. Similar findings were reported in Wong et al (2014), Young et al (2007) and 
Coleman et al (1988) with regards to night laughing where approximately 60%, 75% 
and 83% of their cases were affected (17, 18, 111). Teeth grinding was experienced in 
nearly half of this study cohort and was similar to that reported by Young and 
colleagues (18). Over a quarter of the individuals with RTT in this study had issues with 
daytime napping (36%) and night screaming (28%). Similar patterns to those observed 
by Wong et al and Young et al (17, 18). Studies conducted using large population based 
studies have provided greater precision on the presence and prevalence of sleep 
problems as there was a consistency in the findings portrayed, and the current large 
sample study confirms those findings in an international study.  
This study not only focused on Rett syndrome specific sleep problems but also other 
aspects of sleep disturbances. The Sleep Disturbance Scale for Children is a validated 
sleep assessment tool (106). The questionnaire allowed measurement of various sleep 
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disturbances items faced by RTT individuals and enabled comparison against the 
general population. Findings of this study showed that occurrence of sleep disturbances 
were higher in RTT cases than in normal, healthy individuals in which DIMS, SWTD 
and DOES subscales achieved highest sleep scores and concurred with the findings of 
Bruni et al (1996). Studies have shown that individuals with a disability, whether it be a 
syndrome, neurodegenerative disease or cerebral related disorders, experience 
symptoms of sleep disturbances that are more pronounced than in healthy individuals 
(112, 113).  
A study which looked at the sleep disturbances in individuals with multiple disabilities 
found that nearly three quarter suffered difficulties initiating or maintaining sleep (114). 
It is not uncommon in normally developing individuals during their first few years of 
life to experience difficulties of initiating and maintenance of sleep such as bed 
resistance, sleep duration and latency, night awakenings (115). However, these 
difficulties do not usually persist.  This may not be the same case in individuals with 
disabilities. Findings from this study and other studies show that difficulties in initiating 
and maintaining sleep disturbances are particularly problematic (106, 114). There is a 
possible chance that this effect is caused by cerebellar or cerebral abnormalities 
associated with RTT (29, 116).  Further, an increase in DIMS score within this study 
sample can be related to one specific sleep problem, difficulty falling asleep, which was 
persistent in more than half of the study sample who frequently experienced a difficulty 
in sleep latency. 
Occurrences of sleep problems are also found in other neurodevelopmental disorders. 
Sleep problems occur in different populations with intellectual disabilities (16), and 
autism (117) and in those with genetic syndromes such as Angelman syndrome (71). 
Some studies have also used the SDSC to evaluate sleep disturbances in those with 
intellectual disability such as Autism spectrum disorders and Angelman syndrome and 
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the findings were similar to that of the current study (118, 119). Johnson et al (2012) 
examined sleep disturbances in 124 children diagnosed with Autism Spectrum Disorder. 
The study found that more than three quarters were identified as poor sleepers with 
particularly high scores for the DIMS and SWTD subscales (118). Similarly for 49 
individuals with Angelman syndrome, the prevalence of sleep problems was high in the 
form of disturbances in initiating and maintaining sleep, movement disorders and 
excessive daytime somnolence (119). Research conducted using such validated 
questionnaires across different diagnostic groups provides greater understanding of the 
sleep disturbances that are commonly problematic for individuals with an intellectual 
disability.  
4.3 Age: an influencing factor of sleep  
 
Over a typical lifespan, the total amount of time spent sleeping each day decreases and 
consolidates overtime as age progresses. This pattern isn’t evident in those who are 
affected with Rett syndrome. Studies conducted since 1990’s have reported impaired 
sleep patterns in individuals with RTT and have shown that age related decreases in 
total and daytime sleep in normal individuals aren’t observed in those affected with 
RTT (75, 81). Added to that, recent studies showed RTT specific sleep problems 
appeared to vary with age (17, 18). From the findings of the current study, difficulty 
falling asleep, night laughing and teeth grinding were highest in children under the age 
of seven and decreased as they aged. However, night waking and daytime napping 
tended to increase with age. A similar pattern was also identified in those individuals 
who attained high sleep disturbances scores where the total sleep disturbance score and 
five subscale scores were shown to be highest in children aged less than seven years. 
Studies have looked upon sleep problems and disturbances in relation to age and little is 
known as to what factors have actually contributed to the decline of some sleep 
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problems with age and not to other problems (17, 18, 81). When younger, the total 
number of hours slept in a 24 hours period cycle is higher and same as with daytime 
sleep. Then again as age progress, the total sleep time gets decreased and the daytime 
sleep will not usually be required after 4 years of age (120). This is not found in 
individuals with RTT as studies have shown that the total number of hours spent on 
sleeping and daytime sleep do not decrease with age but rather increase with age (75, 
81). Some authors have hypothesized that developmental arrest of brain growth in RTT 
cases could be a possible reason as to why total and daytime sleep time doesn’t decrease 
when compared to normal, healthy individuals (81).   
Developmental regression characterized by the loss of hand and communication skills is 
a key criterion when making a confirmed clinical diagnosis of RTT (21).  It occurs 
when individuals have an early normal developmental stability. A study by Fehr et al 
(2011) showed that individuals who regressed early in their life were less likely to learn 
to talk or walk when compared to individuals with later regression. Another study 
showed that individuals with an early regression experienced poorer gross motor 
development (121). It could be that some individuals might have had an early regression 
at a very young age and others would be still regressing. This difference in regression is 
shown to affect their gross motor development and could be why sleep problems appear 
more prominently when younger. 
Daytime napping and night waking decrease with age in normal individuals. This is not 
observed in those affected with RTT. In fact, this study’s findings show that daytime 
napping and night waking increase with age. This study also found out that epilepsy is 
present in some individuals and that the seizure activity varied among individuals from 
rare to uncontrolled seizures. It is thought that the presence and persistence of specific 
sleep problems in older individuals may be affected by the sedative effects of anti-
epileptic medications used (122, 123), possibly influencing daytime napping. A 2000 
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study pointed out that ideal antiepileptic drug (AED), do interfere with proper sleep, by 
daytime somnolence and suggested these type of medications to be administered with 
minimal effective dosage, and paying attention to the time of hours of administration 
(123). These possible causes could be the reason as to why the prevalence of some sleep 
problems were high when in young children and others when older.  
4.4 MECP2 mutation: Effect of various mutation types on sleep problems 
 
Over 200 types of MECP2 mutation have been identified and each type is linked with 
multiple disciplines of clinical phenotypes such as early development (1) and the 
prevalence of comorbidities in Rett syndrome such as epilepsy and scoliosis (124) and 
clinical severity (46). Based on the clinical phenotypic severity, some mutations 
including large deletion, p.Arg270* and p.Arg255* are associated with severe 
phenotype while p.Arg294* and p.Arg133Cys are associated with milder clinical 
presentation (46, 125). The current study has shown some variation in the effect of age 
on sleep problems and also some variation attributable to mutation type. Overall, 
specific sleep problems and disturbances were mostly severe in p.Arg294* mutation 
type, a mutation type that has been described in past literature to have milder phenotype 
(46).  
Each MECP2 mutation types has been shown to be associated with behavioural 
phenotype in individuals with RTT (126). Robertson et al (2006) mentioned individuals 
with p.Arg294* mutation type exhibit behaviours such as mood difficulties, fear and 
anxiety or body rocking. The behavioural phenotypes mentioned above are similar to 
sleep disturbance items in the DIMS subscale, “falling asleep anxiety” (106). Even 
though p.Arg294* mutation types is identified with milder clinical course, the 
behaviours associated with it seemed to be severe and it is possible severe behavioural 
phenotypes could also affect sleep.  Studies have also shown that individuals with 
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p.Arg294* mutation experience an early regression, around after 18 months of age (1, 
121). Since, this study found that specific sleep problems and sleep disturbances were 
high in those who had a p.Arg294* mutation type and in the youngest age group, RTT 
cases who were less than seven years of age may have regressed at an early stage, may 
be at or around 18 months of age which have affected their gross motor profile and this 
could be possible chance as to why this type of MECP2 mutation may have presented 
with a high severity of sleep problems. However, the relationship between specific sleep 
problems and MECP2 mutation type is not well understood and as yet unidentified 
pathophysiological mechanisms likely play a role.   
4.5 Additional factors influencing sleep: Epilepsy and Mobility 
 
One of the common comorbidities associated with Rett syndrome is epilepsy and is 
estimated to occur in around 81% in a study cohort (52). This study observed whether 
there was a relationship between seizure activities and sleep disturbances and found 
severe seizures were associated with poorer sleep as it was evident from the increased 
odds ratio in total, SWTD and DOES sleep disturbance scores compared to those whose 
seizure were controlled or had no history of epilepsy. A correlation between age, 
mutation type and epilepsy was established as seizure activity was problematic in the 
youngest age group and those who had p.Arg294* mutation type with increased sleep 
disturbance scores.                       
Studies have provided the evidence that the incidence of seizures in an individual have 
profound effects on sleep architecture and could even last longer than the postictal 
period. Studies show that persistent daytime tiredness and impaired quality of life was 
associated in patients with epilepsy (127-129). Nevertheless, research on the effect of 
epilepsy on sleep symptoms in RTT cases are limited. However, a study by Aldrich et al 
(1990)Meanwhile, several studies have investigated epilepsy in Rett syndrome based on 
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age and mutation type. Two large population-based studies reported that the onset and 
severity of seizure activity is usually observed between seven to 17 years of age (131, 
132). However, a recent study conducted in 2010, using information on 1120 patients 
from a Israeli Rett Centre showed that the onset of seizure activity has occurred during 
regression period in some RTT individuals and has been reported in individuals as 
young as 1 month of age (133). Similar findings were observed from this study where 
severe seizure activity was reported in those aged less than seven years.  
An Italian study conducted in 2010 looked at the relation between seizure activity and 
genotype and reported epilepsy commonly occurred in their study cohort who had a 
p.Arg294* mutation type which was similar to our findings, in contrast to the Israeli 
study which found no relationships between MECP2 mutation type and epilepsy (133, 
134).  
The current study further looked at the correlation between sleep disturbance and 
mobility of the affected individual.  Taking into account the effects of age, mutation 
type, epilepsy and scoliosis into account, total and DOES  sleep scores were high in 
those who were immobile and those who were younger than seven years, with a 
p.Arg294* mutation type and with uncontrolled seizures. No studies have particularly 
focused on physical ability such as walking of RTT individuals in relation to sleep 
problems and studies are yet to provide evidence on sleep problems in relation to 
mobility in RTT. However, a linkage between epilepsy and mobility in RTT was 
reported by Jian et al using a large international cohort in 2007. They found  that 
participants who had poor mobility or were immobile tend to have a high risk of 
developing epilepsy (52), both these symptoms reflecting a more severe phenotype.  
Further, this study looked at the effect of Scoliosis on any sleep disturbances. Our 
findings showed that there was no effect of Scoliosis on the sleep disturbances items by 
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taking into account the effects of age, mutation types, epilepsy and mobility. It was 
thought that a mild or severe curvature will impact the sleep onset or regulation of a 
child as a normal sleeping posture would be disrupted by the spinal curvature. In 
addition, it was also assumed that having a spinal fusion done would make an 
improvement in the sleeping position of the child thus causing less disturbance to sleep. 
However, no studies have been conducted to look at the relationships between sleep 
problems and scoliosis in individuals affected with RTT and further focus must be given 
to this research area in the near future.  
4.6 Effect of behavioural and pharmacological strategies on sleep problems  
 
Management of sleep problems in RTT includes both behavioural and pharmacological 
strategies which is evident from this study’s findings. Behavioural treatments were used 
by the majority and were perceived to be more effective when compared to the thirteen 
different pharmacological medication types being used.  
The score of sleep hygiene was used in this study to measure its relation with the 
prevalence and persistence of any specific sleep problem type. It was found that sleep 
hygiene only had a mere effect on night screaming but not any other sleep problem. 
With regards to past studies, sleep hygiene was reported to have increased effectiveness 
on RTT individuals with sleep dysfunction. Behavioural strategies have been used in 
RTT cohort since early 1990’s.  Piazza et al (1991) conducted the first study using a 
sample of three girls and found that by administering fading procedure as a strategy, 
sleep patterns were more regulated and the families reported their girls having more 
night-time sleep (83). No studies were further done thereafter the publication of Piazza 
et al. Despite that, several studies have been published that focused on sleep hygiene in 
children with developmental disabilities. A study conducted in 2008 which looked at the 
effectiveness of sleep hygiene in children with developmental disabilities mentioned 
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that the first line of sleep treatment should be sleep hygiene as it is regarded as the best 
set of sleep behaviour that would prepare and promote a person to have a timed and 
effective sleep (135) in which another study did also report similar findings to that of 
the 2008 study (136). The 2008 study further explained that by using sleep hygiene, it 
entrains the intrinsic circadian rhythms to the 24 hours cycle and the external 
environment of an individual in which other studies have also evidenced this finding 
(135, 137, 138).  
Weighted blanket was one among the behavioural management that has being used by 
most families. Weighted blankets are shown to improve sleep in individuals particularly 
those who are developmentally disabled. It is reported that weighted blanket promotes 
the production of parasympathetic neurotransmitters such as serotonin and dopamine 
thus increasing the parasympathetic tones and is shown to reduce anxiety and over 
arousal in intellectually disabled individuals (139). Studies are limited to provide 
information on how effective they were in managing sleep problems. However, a study 
had showed the usage of weighted blanket in an autism cohort (140).  Even though the 
literature provides limited evidence to the findings, this study showed behavioural 
strategies administered in a longitudinal study like this suggests behavioural 
management could be more effective in treating sleep problems.  
Among the thirteen pharmacological medications used by the current study cohort, 
melatonin was reported by parents to be the most effective. Previous studies have 
mentioned the usage of melatonin in individuals with developmental disabilities but not 
particularly with RTT. Past evidences have reported melatonin to be a safe and well-
tolerated sleep treatment in those who were affected by a developmental disability (141, 
142).  




This was the first study to date that has looked at specific sleep problems and sleep 
disturbances in RTT by using a large international study cohort. In addition, the study 
measured the presence and prevalence of sleep problems by taking into account the 
effects of multiple factors that influenced the sleep problems. One of the main 
limitations of this study was, not all values were statistically significant. It was a small 
sample size with regards to the factors analysed. Another limitation to be considered 
was that gender difference was not taken into account for this study since most of the 




Chapter 5: Conclusion 
 
Our current study has investigated the presence and prevalence of sleep problems over 
time in a large sample. The study also further described the parents’ perception of the 
effectiveness of the treatments used on the affected child. Considering the limitations of 
this study, future research should focus on the correlation between sleep hygiene and the 
occurrence of sleep problems. In addition, it would be beneficial to look at the effect of 
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The InterRett Study 
                                2015 
                                                                 
                 ID: _________________ 
We welcome your participation in this follow-up questionnaire about Rett syndrome, 
which focuses on respiratory and sleep issues. Thank you for taking part in this study 
and spending the time to fill in this questionnaire.  
Please return the completed questionnaire in the envelope provided. If you have any 
queries about the study in general or any aspect of this questionnaire, please do not 
hesitate to contact: 
   Dr Helen Leonard (Medical Director) 
   Phone: +61 8 94897790 
   Fax: +61 8 94897700 
   Mobile:+61 0419956946 
   Email: Rett@telethonkids.org.au 
   Web: interrett.org.au 
 
 





INTERRETT FOLLOW-UP STUDY 2015 
THE PURPOSE OF THIS QUESTIONNAIRE IS TO COLLECT INFORMATION ABOUT YOUR 
DAUGHTER’S HEALTH, ESPECIALLY ANY BREATHING AND SLEEPING PROBLEMS SHE MIGHT 
HAVE. WE THANK YOU FOR TAKING PART IN THIS STUDY AND FILLING IN THIS 
QUESTIONNAIRE.  
THERE ARE THREE SECTIONS OF THIS STUDY 
1. PARTICIPANT INFORMATION 
2. FAMILY CONSENT 
3. BREATHING AND SLEEP HEALTH QUESTIONNAIRES 
 
4. FAMILY HEALTH QUESTIONNAIRES 
THE PARTICIPANT INFORMATION SHEET DESCRIBES WHAT OUR STUDY IS ABOUT. 
YOUR CONSENT TO PARTICIPATE IN THIS STUDY WILL BE REQUESTED FOLLOWING THE 
INFORMATION SHEET. PLEASE MARK THE BOX IN THE ATTACHED CONSENT FORM IN ORDER 
TO DOCUMENT YOUR PARTICIPATION IN THIS STUDY. 
AS YOU WORK THROUGH THE QUESTIONNAIRE, YOU WILL SEE TWO MAIN TYPES OF 
QUESTIONS: 
A) QUESTIONS TO WHICH OPTIONS HAVE NOT BEEN SUPPLIED. YOU WILL BE ABLE TO 
WRITE YOUR ANSWER IN THE SPACE PROVIDED. 
B) QUESTIONS TO WHICH ALTERNATIVE OPTIONS HAVE BEEN SUPPLIED (E.G. YES OR 
NO). YOU WILL BE ASKED TO CHOOSE THE BEST ANSWER FOR YOU OR YOUR 
DAUGHTER. 
AT THE END OF EACH SECTION YOU WILL BE ASKED TO PROVIDE GENERAL COMMENTS. 
THESE TEXT BOXES ARE OPTIONAL AND WILL GIVE YOU AN OPPORTUNITY TO DESCRIBE 
YOUR EXPERIENCES IN GREATER DETAIL.  
IF YOU REQUIRE ASSISTANCE WHILE COMPLETING YOUR QUESTIONNAIRE, PLEASE CONTACT 








PARTICIPANT INFORMATION  
Breathing and sleep health in Rett syndrome 
 
Chief Investigator:  
Professor Helen Leonard, Telethon Kids Institute, UWA, Perth 




Dr Jenny Downs, Telethon Kids Institute, Perth 
Associate Professor Kim Carter, Telethon Kids Institute, Perth 
Jessica Mackay, Honours student, University of Western Australia, Perth 
Sharolin Boban, Honours student, Murdoch University, Perth 
 
You have been invited to participate in our new study about your child’s breathing and sleep health. 
This information sheet describes what our study is about and there will be further opportunity to 
discuss this study with us as well. 
The aim of the study 
This study will investigate breathing and sleep problems and how these problems are managed in 
girls and women with Rett syndrome.  
Why are we doing this study? 
Breathing and sleep problems occur commonly in Rett syndrome. They can have marked impacts on 
the lives of the girls and women with Rett syndrome and their families. Whilst there is some 
information available, there is a lack of comprehensive information about these problems and how 
they are managed. We aim to collect information about the occurrence and treatment of breathing 
and sleep problems from a large number of families who have a daughter with Rett syndrome.   
Why was I invited to participate in the study? 
You have been invited to participate in this study because you have participated in the InterRett 
study and previously filled out an InterRett questionnaire about a child or adult with Rett syndrome 
in your family.  
Do I have to take part? 
No, your do not have to take part. Taking part in this research is entirely your decision and even if 
you have agreed to take part, you can decide to withdraw at any time if you want to.  
Is there likely to be a benefit to my child?   
There is unlikely to be a specific benefit for your child although you may value the opportunity to 
reflect on your daughter’s health and wellbeing.  
Is there likely to be a benefit to other people in the future? 
This research will help us to understand the impacts and management of breathing and sleep 
problems in Rett syndrome. By combining the reports of a large number of families, we hope to 
provide clear information about these health issues to families and clinicians. We will put a summary 
of our results on our website for you to read. 
What will I be asked to do if you decide to take part in this study? 
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If you agree to participate in this study, we will send you a questionnaire either online or by post, 
depending on your preference. The questionnaire will include questions about the health of your 
daughter in general and particular questions about her breathing patterns, any chest infections she 
has had and her sleeping. We will also ask questions about any medications and other treatments 
your daughter received for these issues and how helpful these treatments were. The questionnaire 
has some questions about your health and the quality of life of your family. 
What are the possible risks, discomforts or inconveniences? 
Completing the questionnaire will take approximately 30 to 90 minutes of your time. You can 
complete in more than one sitting. The issues relate to your day to day experiences with your 
daughter. If you do have concerns that arise from completing the questionnaire, you can contact Dr 
Helen Leonard in the first instance there are any concerns. Her contact details are at the top of this 
information sheet. 
What will happen to the information I provide? 
All information you provide will be stored in a locked cabinet or on a secure, password-protected 
network at the Telethon Kids Institute in Perth, Western Australia. Only authorized study personnel 
will have access to your data. This is a requirement of the Human Research Ethics Committee at the 
University of Western Australia. Once the study is complete, your data will continue to be protected 
in this way.  
What about my privacy? 
You daughter will be allocated the same unique study identification number that she had when you 
completed the initial InterRett family questionnaire. This number will remain confidential to the 
investigators and be used in all data analysis. No named or identifiable data will be included in any 
subsequent reports, publications or presentations. 
Who has approved the study? 
Approval to conduct this research has been provided by the University of Western Australia, in 
accordance with its ethics review and approval procedures. Any person considering participation in 
this research project, or agreeing to participate, may raise any questions or issues with the 
researchers at any time. 
 
In addition, any person not satisfied with the response of researchers may raise ethics issues or 
concerns, and may make any complaints about this research project by contacting the Human Ethics 
Office at the University of Western Australia on +61 8 6488 3703 or by emailing to 
humanethics@uwa.edu.au . 
All research participants are entitled to retain a copy of any Participant Information Form and/or 
Participant Consent Form relating to this research project. 
 






I have read the information provided and any questions I have asked have been answered to 
my satisfaction. I agree to complete the questionnaire to the best of my ability, realising 
that I may withdraw at any time without reason and without prejudice. 
I understand that all identifiable (attributable) information that I provide is treated as 
strictly confidential and will not be released by the investigator in any form that may 
identify me. 
I have been advised in the information sheet and/or on the telephone as to what data is 
being collected, the purpose for collecting the data, and what will be done with the data 
upon completion of the research. 
I agree that research data gathered for the study may be published provided my name or 
other identifying information is not used. 





Section 1 – About You and Your Family 
1. Which of the following best describes the person answering most of the questions in 







☐Other family member, please specify: _______________________ 
☐Carer, please specify length of time in care: ________________________ 
 




☐Other, please describe: _____________________ 
 
If employed, what is the job title? _______________________ 
 




☐Other, please describe: _____________________ 
 
If employed, what is the job title? _______________________ 
 
For ease of responding, we will hereafter refer to the person you are completing the 
questionnaire for as “your daughter”.  
 
4. Where does your daughter live the majority of the time? (Please tick ONE box only) 
☐Parental home 
☐Group home or Community residential unit 
☐Hostel  
☐Hospital or Nursing home 
☐Other, please describe: _______________________ 
 
 
Please go to Section 2 on the next page.
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Section 2 – About Your Daughter 
At the end of this section you will be asked to provide general comments. These text 
boxes are optional and will give you an opportunity to describe your experiences in 
greater detail.  
1. Has your daughter had MECP2 genetic testing?  
☐Yes 
☐No, please go to Question 4 
 
2. Was a MECP2 mutation found? 
☐Yes 
☐No, please go to Question 4 
 
3. What is the MECP2 mutation type that she has? (Please tick ONE box only) 
☐C-terminal  
☐Early truncation  
☐Large deletion  
☐p.Arg106Trp (R106W) 
☐p.Arg133Cys (R133C)  
☐p.Arg168* (R168X)  
☐p.Arg255* (R255X) 
☐p.Arg270* (R270X)  
☐p.Arg294* (R294X)  
☐p.Arg306Cys (R306C) 
☐p.Thr158Met (T158M)  
☐Other, please specify: ___________ 





4. What is her current ability to sit with no back support? (e.g. on the edge of her 
bed) (Please tick ONE box only) 
☐Unable to sit, please go to question 6 
☐Sits with assistance from a person 
☐Sits with no assistance 
 
5. If she can sit on her own or with assistance, how long can she sit for (e.g. 2 seconds 
or 1 minute)? 
___seconds or _____minutes 
 
6. What is her current ability to stand? (Please tick ONE box only) 
☐Unable to stand, please go to Question 8 
☐Stands with assistance from a person or standing frame 
☐Stands with no assistance 
 
7. If she can stand on her own or with assistance, how long can she stand for (e.g. 2 
seconds or 1 minute)? 








8. What is her current ability to walk? (Please tick ONE box only) 
☐Unable to walk, please go to Question 10 
☐Walks with assistance from a person or walking aid  
☐Walks with no assistance on level surfaces 
☐Walks with no assistance on all surfaces 
 
9. If she can walk on her own or with assistance, how far can she walk? 
____ metres or ___ feet 
 
10. How does she currently use her hands? Please mark all that apply. 
☐Able to push a switch 
☐Able to pick up an object such as eating utensil or cup 
☐Able to finger feed 
☐Able to pick up small things (i.e. the size of a sultana or raisin) 
☐Able to transfer an object from one hand to the other 
 
11. What are her best current language skills? (Please tick ONE box only) 
☐No sounds 
☐Babble or jargon  
☐Word approximation 
☐Single words 
☐Two word sentences  
☐Three or more word sentences 
 














Section 3 – Your Daughter’s General Health and Wellbeing 
If in this section or any other you are finding it difficult to recall the exact age of your 
daughter, or the date of a specific event (e.g. hospitalisation), it may be helpful to think 
back to what was happening around the time of the event. For example: Where were you 
living? What school was your daughter attending? 







2. Has your daughter EVER had been diagnosed with EPILEPSY? 
☐No, please go to Question 10  
☐Yes 
 
3. How old was she when she started to have FITS or SEIZURES? 
____ years and ____ months 
 
4. How often does she currently have a FIT or SEIZURE? (Please tick ONE box only) 
☐Seizures are not controlled (daily/more than once a week) 
☐Seizures occur frequently (once per week) 
☐Has occasional seizures (once per month) 
☐Rarely has a seizure any more (once or twice per year) 
☐Completely under control 
 
5. Does she have a Vagal Nerve Stimulator (VNS) for management of her epilepsy? 
☐No, please go to Question 9 
☐Yes 
 
6. How old was your daughter when she had the VNS?____ years and ____ months 
 




8. Does the VNS appear to have altered the regularity of her breathing?  

















10. Has your daughter been diagnosed with SCOLIOSIS? 
☐No, please go to Question 17 
☐Yes 
 
11. How old was she when SCOLIOSIS was diagnosed?  ____ years and ____ months 
 
12. Has she had surgery for her SCOLIOSIS? 
☐No, please go to Question 14 
☐Yes 
 
13. How old was she when she had SCOLIOSIS surgery?   
____ years and ____ months  
Please go to Question 16 
 




15. How you know it is mild or severe? Please provide your daughter’s latest Cobb 





















17. Has your daughter ever had any BROKEN (fractured) BONES? 
☐No, please go to Question 19  
☐Yes, please record details of the fracture(s) in the following table. 
 
What bone was 
broken? 
When did it 
happen? 
How did the 
facture occur? 
How was it 
treated? 
Example answer 
Leg-femur 15/02/2014 OR 6 
years 
Fell from bed Had a full leg cast 
Approx. 8 weeks 
Your answer 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 





    
 
 
    
 
 
    
 
 










19. Does your daughter have any of the following health issues currently? 
 






Please select the 
extent this 
condition impacts 
her daily life 
Please describe the 































Please select the 
extent this 
condition impacts 
her daily life 
Please describe the 












































☐ ☐ Cold feet       
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Please select the 
extent this 
condition impacts 
her daily life 
Please describe the 






























(e.g. cold on a 
hot day; 
overheating on 
a hot day) 
 















☐ ☐ Hip dislocation        
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Please select the 
extent this 
condition impacts 
her daily life 
Please describe the 

























































Please select the 
extent this 
condition impacts 
her daily life 
Please describe the 

























Please go to Section 4 on the next page.
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Section 4 – Medications 
1. Please list in the table below all of the REGULAR MEDICATIONS and SUPPLEMENTS 
that your daughter is CURRENTLY taking. We would like you to include prescription 
and non-prescription medications, and vitamin, mineral and food supplements, as 
well as anything from alternative therapists. 
Name of medication or 
supplement 
Total dose of medication or 
supplement given per day (mg 
or ml) 
Please specify what the 
medication or supplement 
is used for 
Example answers 
Depakote Two 100 mg tablets given 
three times a day  
Epilepsy 
 





































   
 
   
 
   
 
   
 





Please go to Section 5a on the next page.
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Section 5a – Breathing Irregularities 
Think about your child during the past 3 months. How often does she have the following breathing irregularities? What impact do they have 
on her daily life?  
Symptoms 
 
How often? How much of an impact does 
this condition have on her 
daily life? 




































1. Breath holding or apnoea 
episodes 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐  
2. Hyperventilation or panting 
episodes 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐  
3. Episodes of any other 
breathing irregularities 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐  
4. Difficulty breathing during 
the day (for any of the 
breathing irregularities 
above) 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
 
5. Difficulty breathing during 
sleep (for any of the 
breathing irregularities 
above) 
























9. Please describe the impact of your daughter’s other breathing irregularities on your 







10. Have you noticed any specific events or items that trigger or aggravate your daughter’s 
breath holding or apnoea? 
☐No  
☐Yes, please describe: __________________________________________________ 
_____________________________________________________________________ 
 
11. Have you noticed any specific events or items that reduce your daughter’s breath 
holding or apnoea? 
☐No  
☐Yes, please describe: __________________________________________________ 
_____________________________________________________________________ 
 
12. Have you noticed any specific events or items that trigger or aggravate your daughter’s 
hyperventilation or panting? 
☐No  
☐Yes, please describe: __________________________________________________ 
_____________________________________________________________________ 
 
13. Have you noticed any specific events or items that reduce your daughter’s 
hyperventilation or panting? 
☐No  
☐Yes, please describe: __________________________________________________ 
_____________________________________________________________________ 
 
Please go to Section 5b on the next page. 
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Section 5b – Respiratory Symptoms 
These symptoms are not commonly associated with Rett syndrome. However we are 
interested in knowing if your daughter is affected by them.  
Think about your daughter over the past 3 months. How often does she have the following 




How often? How much of an 
impact does this 
condition have on 




































1. Coughing ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
2. Bring up phlegm or 
mucous (thick fluid 
from the chest) 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
3. Chesty or phlegmy 
when breathing 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
4. Episodes of wheezy 
sounding breathing 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
 
 
Please go to Section 5c on the next page. 
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Section 5c – Treatment for Breathing Irregularities 
Breathing irregularities are not well understood in Rett syndrome and are not commonly 
treated. We are interested in finding out what (if any) treatments your daughter might 
have had to manage these breathing irregularities and how you felt they impacted on her 








the treatment? (If 
your own strategy, 
please state this) 
Please rate the effectiveness of 
the treatment 


























☐ ☐ ☐ 
 
 
Please go to Section 6 on the next page. 
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Section 6 – Eating and Drinking 
Please answer the following in relation to your daughter’s current feeding patterns. 
 
1. Please indicate your daughter’s current eating and drinking patterns. 
☐Has all food, drinks/fluids and medication orally.   
☐Has all food, drinks/fluids and medication through a gastrostomy/jejunostomy 
button, or nasogastric tube. 
☐Some combination of oral and tube feeding for food, drinks/fluids and medication. 
☐Some combination of oral and tube feeding for food, drinks/fluids and medication 
when she is unwell.  
 





3. How does your daughter use her feeding tube currently if she is unwell? Please mark 










5. If your daughter has a gastrostomy or jejunostomy button, please indicate WHEN she 
had her first gastrostomy or jejunostomy inserted by giving a DATE or the AGE of your 
daughter at the time. 
Date: _____________________ (e.g. February 2005) 
OR  
Age: ___ years and ___ months (e.g. 3 years; 2 years and 9 months; or 15 months) 
 
6. On average, how long does it take her to complete her main meal of the day?  
(Please tick ONE box only) 
☐0-15 mins  
☐15-30 mins 
☐30-45 mins  
☐45-60 mins  

























7. Does she take regular (unmodified) 
food by mouth? 
☐ ☐ ☐ ☐ ☐ 
8. Does she ever take regular drinks by 
mouth? 
☐ ☐ ☐ ☐ ☐ 
9. Does she require food with modified 
texture (e.g. soft or pureed)? 
☐ ☐ ☐ ☐ ☐ 
10. Does she require thickened drinks 
(or naturally thick drinks)? 
☐ ☐ ☐ ☐ ☐ 
11. If all nutrition is taken by tube, does 
your daughter ever taste food? 
☐ ☐ ☐ ☐ ☐ 
 
Please answer the following in relation to your daughter’s current feeding patterns. 
 















12. Does she ever wheeze, cough or 
sneeze during or after eating, 
drinking or feeds? 
☐ ☐ ☐ ☐ ☐ 
13. Does she ever choke during or after 
eating, drinking or feeds? 
☐ ☐ ☐ ☐ ☐ 
14. Does she ever vomit or regurgitate 
during or after eating, drinking or 
feeds? 
☐ ☐ ☐ ☐ ☐ 
15. Is there anything that tends to make 
her cough or choke during meals? If 
yes, please specify: 
______________________________ 
☐ ☐ ☐ ☐ ☐ 
16. If your daughter takes food by 
mouth, does she have difficulty 
taking food or drinks from other 
people? 
☐ ☐ ☐ ☐ ☐ 
 




____ kg or  ___ pounds 
 
 
18. If you have any other measurements of weight from your past records, please list in 
the table below. 
 
Date (dd/mm/yyyy) Weight Measurement Measurement unit 
  ☐kg☐pounds 
  ☐kg☐pounds 
  ☐kg☐pounds 
  ☐kg☐pounds 
  ☐kg☐pounds 
  ☐kg☐pounds 
 
19. How often do you feel concerned about whether your daughter’s food intake is 
adequate? (Please tick ONE box only) 
☐I do not have any worries about this – she eats an adequate amount. 
☐There are occasional days/periods when I worry (about once a month or when she is 
unwell). 
☐I frequently worry about her food intake (weekly). 
☐I constantly worry about her food intake – it’s never satisfactory.  
 
20. How often do you feel concerned about whether your daughter’s fluid intake is 
adequate? (Please tick ONE box only) 
☐I do not have any worries about this – she drinks an adequate amount. 
☐There are occasional days/periods when I worry (about once a month or when she is 
unwell). 
☐I frequently worry about her fluid intake (weekly). 
☐I constantly worry about her fluid intake – it’s never satisfactory.  
 
 
Please go to Section 7a on the next page. 
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Section 7a – Medical Care 
For the following questions, chest/respiratory infection refers to lower respiratory tract 
infections such as pneumonia or bronchitis. Over the PAST 12 MONTHS, how often has 
your daughter: 
 
 Not at 
all 
Once 2– 3 
times 




1. Visited a clinic or physician’s office 
for chest/respiratory infections? 
☐ ☐ ☐ ☐ ☐ 
2. Had a course of antibiotics for 
chest/respiratory infections? 
☐ ☐ ☐ ☐ ☐ 
3. Been admitted to hospital for 
chest/respiratory infections? 
☐ ☐ ☐ ☐ ☐ 
4. Visited a clinic or physician’s office 
for irregular breathing patterns 
(hyperventilation or breath holding)?  
☐ ☐ ☐ ☐ ☐ 
5. Been prescribed medication for 
irregular breathing patterns 
(hyperventilation or breath holding)? 
☐ ☐ ☐ ☐ ☐ 
6. Been admitted to hospital for 
irregular breathing patterns 
(hyperventilation or breath holding)?  
☐ ☐ ☐ ☐ ☐ 
 
 
Please go to Section 7b on the next page. 
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Section 7b – Hospitalisations 
If your daughter has been admitted to hospital over the PAST 5 YEARS, please describe the 
reason she was admitted, when she was admitted, and the length of stay (specify if you 
know or give an estimation) for each hospitalisation. Please include all hospitalisations, 
even if previously mentioned.  
 
Reason she was 
admitted 
When she was 
admitted 



















































☐ ☐ ☐ ☐ ☐ 
   ☐ ☐ ☐ ☐ ☐ 
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Reason she was 
admitted 
When she was 
admitted 
























☐ ☐ ☐ ☐ ☐ 
 
 
Please go to Section 8a on the next page. 
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Section 8a – Sleeping Problems 
Sleeping problems are not well understood in Rett syndrome. We are interested in finding 


























☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Night 
laughing 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Night 
screaming 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Seizures at 
night 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Teeth 
grinding 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Night 
terrors 
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Waking in 
the night 








☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
Difficulty 
waking 







☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 
 
1. If your daughter has other sleeping problems that were not listed in the table, please 













































We are interested in knowing how much your daughter sleeps. Please answer the 
following questions, keeping in mind your daughter’s CURRENT sleeping patterns. 
 







8. On average, how long after going to bed does your daughter usually fall asleep? 
☐Less than 15 minutes 
☐15-30 minutes 
☐30-45 minutes 
☐45-60 minutes  
☐More than 60 minutes 
 
9. On average, how many times does she wake during the night? ________________ 
 
10. When your daughter wakes up during the night, how long does it usually take her to 
fall back to sleep? ____  hours and ____ minutes 
 
11. On average, how many hours of sleep does your daughter get on most NIGHTS? 





☐More than 11 hours 
 





☐More than 2 hours 
 
 
Please go to Section 8b on the next page. 
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Section 8b – Sleep Hygiene  
1. Please answer the following questions about your daughter's sleep habits by checking 
the best response.  





a. My daughter wakes up at 
about the same time each 
morning. 
☐ ☐ ☐ ☐ ☐ 
b. In the hour before bedtime, 
my daughter engages in 
relaxing activities. 
☐ ☐ ☐ ☐ ☐ 
c. My daughter has drinks or 
foods containing caffeine after 
5 PM (e.g. chocolate, Coca 
Cola). 
☐ ☐ ☐ ☐ ☐ 
d. In the hour before bedtime, 
my daughter engages in 
exciting or stimulating 
activities (e.g. rough and 
tumble play). 
☐ ☐ ☐ ☐ ☐ 
e. My daughter's room is dark 
or dimly lit at bedtime. 
☐ ☐ ☐ ☐ ☐ 
f. My daughter's room is quiet 
at bedtime. 
☐ ☐ ☐ ☐ ☐ 
g. My daughter goes to bed at 
the same time each night. 
☐ ☐ ☐ ☐ ☐ 
h. My daughter follows a 
regular bedtime routine that 
lasts between 15 and 30 min. 
☐ ☐ ☐ ☐ ☐ 
i. I stay in my daughter's room 
until she falls asleep. 
☐ ☐ ☐ ☐ ☐ 
j. After my daughter is tucked 
in, I check on her before she 




k. My daughter watches TV, 
videos, or DVDs to help her fall 
asleep. 
☐ ☐ ☐ ☐ ☐ 
l. My daughter gets exercise or 
activity during the day. 
☐ ☐ ☐ ☐ ☐ 
 
 
Please go to Section 8c on the next page. 
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Section 8c – Sleep Monitoring  
1. Do you monitor your daughter's sleep overnight? 
☐No, please go to Question 3 
☐Yes 
 






3. Are you using smartphone apps to help you manage your daughter's sleep problems? 
☐No, please go to Section 8d 
☐Yes 
 













Please go to Section 8d on the next page. 
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Section 8d – Sleep Treatment 
We are interested in finding out what treatments your daughter might have had to 
manage her sleeping problems. Treatment may be behavioural or exercise related, or 
medication.  
 
Please describe the treatment, when the treatment was started, any side effects your 









Side effects of 
treatment 
Please rate the effectiveness of 
the treatment on her sleep 


























☐ ☐ ☐ 
 
7. Please feel free to provide more information about any treatments you have used to 








Please go to Section 8e on the next page. 
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Section 8e – Sleep Supports and Assessment 
1. Are any of the following supports being used? 
☐Bilevel positive airway pressure (BiPAP) 
☐Continuous positive airway pressure (CPAP) 
☐Supplemental oxygen 
☐EMFIT seizure/movement monitor 
☐Pulse oximetry 
☐Weighted blanket 
☐Other, please describe: _______________________________________________ 
 
2. Has your daughter been admitted to hospital for an assessment of SLEEPING 
PROBLEMS?  
☐No, please go to Section 8e 
☐Yes, please complete the table below 
Date admitted  Hospital where sleeping 
assessment was done 













Please go to Section 8f on the next page. 
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Section 8f – Sleep Disturbance  
Please answer the following statements about your daughter's sleep behaviour over THE 
PAST 6 MONTHS by checking the best response. 
 
Acknowledgement: Bruni et al, 1996. 
 
















1. Your daughter 
goes to bed 
reluctantly. 
☐ ☐ ☐ ☐ ☐ ☐ 
2. Your daughter 
has difficulty 
getting to sleep at 
night. 
☐ ☐ ☐ ☐ ☐ ☐ 
3. Your daughter 
feels anxious or 
afraid when falling 
asleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
4. Your daughter 
startles or jerks 
parts of the body 
while falling asleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
5. Your daughter 
shows repetitive 
actions such as 
rocking or head 
banging while 
falling asleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
6. Your daughter 
sweats excessively 
while failing asleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
7. Your daughter ☐ ☐ ☐ ☐ ☐ ☐ 
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wakes up more 
than twice per 
night. 
8. After waking up 






☐ ☐ ☐ ☐ ☐ ☐ 
9. Your daughter 
has frequent 
twitching or jerking 
of legs while asleep 
or often changes 
position during the 
night or kicks the 
covers off the bed. 
☐ ☐ ☐ ☐ ☐ ☐ 




☐ ☐ ☐ ☐ ☐ ☐ 
11. Your daughter 
gasps for breath or 
is unable to breathe 
during sleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
12. Your daughter 
snores. 
☐ ☐ ☐ ☐ ☐ ☐ 
13. Your daughter 
sweats excessively 
☐ ☐ ☐ ☐ ☐ ☐ 
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during the night. 




☐ ☐ ☐ ☐ ☐ ☐ 
15. You have 
observed your 
daughter talking in 
her sleep. 
☐ ☐ ☐ ☐ ☐ ☐ 
16. Your daughter 
grinds her teeth. 
☐ ☐ ☐ ☐ ☐ ☐ 
17. Your daughter 
wakes from sleep 
screaming or 
confused so that 
you cannot seem to 
get through to her. 
☐ ☐ ☐ ☐ ☐ ☐ 





☐ ☐ ☐ ☐ ☐ ☐ 
19. Your daughter is 
unusually difficult 
to wake up in the 
morning. 
☐ ☐ ☐ ☐ ☐ ☐ 
20. Your daughter 
awakes in the 
morning feeling 
☐ ☐ ☐ ☐ ☐ ☐ 
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21. Your daughter 
feels unable to 
move when waking 
up in the morning. 
☐ ☐ ☐ ☐ ☐ ☐ 




☐ ☐ ☐ ☐ ☐ ☐ 





☐ ☐ ☐ ☐ ☐ ☐ 
 
 










Please go to Section 9 on the next page. 
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Section 9 – Self-Assessment of Personal Health 
The state of one's health may be of extra importance for a parent caring for a child with 
Rett syndrome. The following questions ask for your views about your health.  
Acknowledgement: Ware, Kosinski and Keller, 1996 







2. This question is about activities you might do during a typical day. Does your health 
now limit you in these activities? If so, how much? 





limited at all 
a. Moderate activities, such as moving 
a table, pushing a vacuum cleaner, 
bowling or playing golf. 
☐ ☐ ☐ 
b. Climbing several flights of stairs.  ☐ ☐ ☐ 
 
3. During the PAST 4 WEEKS, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? 
 
 Yes No 
a. Accomplished less than you would like. ☐ ☐ 
b. Were limited in the kind of work or other activities. ☐ ☐ 
 
4. During the PAST 4 WEEKS, have you had any of the following problems with your work 
or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 
 Yes No 
a. Accomplished less than you would like. ☐ ☐ 
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5. During the PAST 4 WEEKS, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
☐Extremely 
☐Quite a bit 
☐Moderately 
☐A little bit 
☐Not at all 
 
6. This question is about how you feel and how things have been with you during the 
PAST 4 WEEKS. Please choose the answer that comes closest to the way you have been 
feeling.  
 
How much of the time during the PAST 4 WEEKS.... 
 
















a. Have you felt 
calm and peaceful? 
☐ ☐ ☐ ☐ ☐ ☐ 
b. Did you have a 
lot of energy? 
☐ ☐ ☐ ☐ ☐ ☐ 
c. Have you felt 
downhearted and 
blue? 
☐ ☐ ☐ ☐ ☐ ☐ 
 
7. During the past 4 WEEKS, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
☐All of the time 
☐Most of the time 
☐A good bit of the time 
☐Some of the time 
☐A little of the time 
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☐None of the time 
 
8. Please discuss the impact that having a daughter with Rett syndrome has had on the 









Please go to Section 10 on the next page. 
Section 10 – Family Quality of Life 
This section is about how you feel about life together as a family. Your family may include 
many people - mother, father, partners, children, aunts, uncles, grandparents, etc. For this 
section, please consider your family as those people: who think of themselves as part of 
your family (even though they may or may not be related by blood or by marriage), and 
who support and care for each other on a regular basis. DO NOT think about relatives 
(extended family) who are only involved in your family once in a while. Please think about 
your family life over the PAST 12 MONTHS.  
 
The items below are things that hundreds of families have said are important for a good 
family quality of life. We want to know how SATISFIED you are with these things in your 
family.  
 
Please choose the option that best reflects your level of satisfaction with each item.  
 
It is important that you answer as many questions as you can but please feel free to skip 
those questions that make you uncomfortable.  
 
Acknowledgement: Hoffman, Marquis, Poston et al, 2006. 
 





Dissatisfied Neither Satisfied Very 
Satisfied 
1. My family enjoys 
spending time together. 
☐ ☐ ☐ ☐ ☐ 
2. My family members 
help the children learn 
☐ ☐ ☐ ☐ ☐ 
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Dissatisfied Neither Satisfied Very 
Satisfied 
to be independent. 
3. My family has the 
support we need to 
relieve stress. 
☐ ☐ ☐ ☐ ☐ 
4. My family members 
have friends or others 
who provide support. 
☐ ☐ ☐ ☐ ☐ 
5. My family members 
help the children with 
schoolwork and 
activities. 
☐ ☐ ☐ ☐ ☐ 
6. My family members 
have transportation to 
get to the places they 
need to be. 
☐ ☐ ☐ ☐ ☐ 
7. My family members 
talk openly with each 
other. 
 
☐ ☐ ☐ ☐ ☐ 
8. My family members 
teach the children how 
to get along with others. 
☐ ☐ ☐ ☐ ☐ 
9. My family members 
have some time to 
pursue our own 
interests. 
☐ ☐ ☐ ☐ ☐ 
10. Our family solves 
problems together. 
☐ ☐ ☐ ☐ ☐ 
11. My family members 
support each other to 
☐ ☐ ☐ ☐ ☐ 
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Dissatisfied Neither Satisfied Very 
Satisfied 
accomplish goals. 
12. My family members 
show they love and care 
for each other. 
☐ ☐ ☐ ☐ ☐ 
13. My family has 
outside help available to 
us to take care of special 
needs of all family 
members. 
☐ ☐ ☐ ☐ ☐ 
14. Adults in our family 
teach the children to 
make good decisions. 
☐ ☐ ☐ ☐ ☐ 
15. My family gets 
medical care when 
needed. 
☐ ☐ ☐ ☐ ☐ 
16. My family has a way 
to take care of our 
expenses. 
☐ ☐ ☐ ☐ ☐ 
17. Adults in my family 
know other people in 
the children's lives 
(friends, teachers, etc.) 
☐ ☐ ☐ ☐ ☐ 
18. My family is able to 
handle life's ups and 
downs. 
☐ ☐ ☐ ☐ ☐ 
19. Adults in my family 
have time to take care 
of the individual needs 
of every child. 
☐ ☐ ☐ ☐ ☐ 
20. My family gets 
dental care when 
☐ ☐ ☐ ☐ ☐ 
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21. My family feels safe 
at home, work, school, 
and in our 
neighbourhood. 
☐ ☐ ☐ ☐ ☐ 
22. My family member 
with a disability has 
support to accomplish 
goals at school or at 
workplace. 
☐ ☐ ☐ ☐ ☐ 
23. My family member 
with a disability has 
support to accomplish 
goals at home. 
☐ ☐ ☐ ☐ ☐ 
24. My family member 
with a disability has 
support to make friends. 
☐ ☐ ☐ ☐ ☐ 
25. My family has good 
relationships with the 
service providers who 
provide services and 
support to our family 
member with a 
disability. 
 
☐ ☐ ☐ ☐ ☐ 
 
 
Please go to Section 11 on the next page. 
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Section 11 – General Comments 
Please use this space to make any further comments about any aspect covered in 
this questionnaire, or anything about Rett syndrome and related disorders in 






































We would encourage you to MAKE A COPY OF YOUR RESPONSES. 
Please then send your completed responses to the following post mail address: PO 
















Table 3: Univariate analyses of the relationships between occurrence of night screaming, mutation type and use of 
sleep hygiene strategies (n=291).                                                     
                                                                                                                                                                                           




CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each 
participant 
‘*’ represents the stop codons of the related genotypes




ORa (95% CIb) p value 
Mutation type      
Large deletion 18 (8.3) 3 (4.0) baseline baseline 
C terminal deletion 22 (10.2) 10 (13.3) 2.73 (0.65,11.43) 0.170 
Early truncating 14 (6.5) 3 (4.0) 1.29 (0.22,7.37) 0.778 
p.Arg106Trp 12 (5.6) 1 (1.3) 0.5 (0.05,5.39) 0.568 
p.Arg133Cys 15 (6.9) 7 (9.3) 2.8 (0.61,12.75) 0.183 
p.Arg168* 20 (9.2) 7 (9.3) 2.1 (0.47,9.36) 0.331 
p.Arg255* 23 (10.6) 8 (10.7) 2.09 (0.48,9.02) 0.324 
p.Arg270* 17 (7.5) 4 (5.3) 1.41 (0.27,7.26) 0.680 
p.Arg294* 14 (6.5) 10 (13.3) 4.29 (0.99,18.59) 0.052 
p.Arg306Cys 17 (7.9) 6 (8.0) 2.12 (0.46,9.84) 0.338 
p.Thr158Met 19 (8.8) 7 (9.3) 2.21 (0.49,9.89) 0.299 
Other 25 (11.6) 9 (12.0) 2.16 (0.51,9.12) 0.295 
Sleep hygiene     
Total scorec - - 2.22 (1.02,4.84) 0.045 
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Table 5: Univariate analyses of the relationships between occurrence of night waking, age group, mutation type and use of sleep hygiene strategies (n=289). 
                                                                                          
 
 Did not occur (n=69) Sometimes (n=74) Often (n=146) 
n (%) n (%) ORa (95% CIb) p value n (%) ORa (95% CIb) p value 
Age group        
0-7 years 13 (18.8) 12 (16.2) baseline baseline 19 (13.0) baseline baseline 
8-12  years 19 (27.5) 24 (32.3) 1.37 (0.51,3.68) 0.534 45 (30.8) 1.62 (0.67,3.93) 0.286 
13-17  years 21 (30.4) 17 (23.0) 0.88 (0.32,2.41) 0.799 35 (24.0) 1.14 (0.47,2.77) 0.772 
18 and older 16 (23.2) 21 (28.4) 1.42 (0.51,3.94) 0.498 47 (32.2) 2.01 (0.81,4.97) 0.131 
Mutation type        
Large deletion 4 (5.8) 6 (8.1) baseline baseline 11 (7.5) baseline baseline 
C terminal deletion 7 (13.5) 7 (9.4) 0.67 (0.13,3.45) 0.13 18 (12.3) 0.94 (0.22,3.94) 0.22 
Early truncating 6 (8.7) 6 (8.1) 0.67 (0.12,3.64) 0.12 5 (3.4) 0.30 (0.06,1.58) 0.06 
p.Arg106Trp 4 (5.8) 2 (2.7) 0.33 (0.04,2.77) 0.04 8 (5.5)  0.73 (0.14,3.82) 0.14 
p.Arg133Cys 2 (2.9) 5 (6.8) 1.67(0.21,13.22) 0.21 12 (8.2) 2.18 (0.33,14.36) 0.33 
p.Arg168* 4 (5.8) 6 (8.1) 1 (0.17,5.98) 0.17 16 (11.0) 1.45 (0.30,7.09) 0.30 
p.Arg255* 11 (15.9) 8 (10.8) 0.48 (0.10,2.30) 0.10 12 (8.2) 0.40 (0.10,1.62) 0.10 
p.Arg270* 3 (4.3) 5 (6.8) 1.11 (0.16,7.51) 0.16 13 (8.9) 1.58 (0.29,8.61) 0.29 
p.Arg294* 6 (8.7) 2 (2.7) 0.22 (0.03,1.71) 0.03 16 (11.0) 0.97(0.22,4.26) 0.22 
p.Arg306Cys 6 (8.7) 13 (17.6) 1.44 (0.29,7.10) 0.29 4 (2.7) 0.24 (0.04,1.33) 0.04 
p.Thr158Met 7 (13.5) 4 (5.4) 0.38 (0.07,2.22) 0.07 15 (10.3) 0.78 (0.18,3.34) 0.18 
Other 9 (13.0) 10 (13.5) 0.74 (0.16,3.50) 0.16 16 (11.0) 0.65 (0.16,2.64) 0.16 
Sleep hygiene        





CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes.  
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Table 7: Univariate analyses of frequency of difficulties falling asleep in relation to age group, mutation type and use of sleep hygiene strategies (n=291). 
 
 
Did not occur (n=117) Sometimes (n=82) Often (n=92) 
n (%) n (%) ORa (95% CIb) p value n (%) ORa (95% CIb) p value 
Age group        
0-7 years 10 (8.5%) 16 (19.5) baseline baseline 18 (19.6) baseline Baseline 
8-12  years 39 (33.3) 20 (24.4) 0.32 (0.12,0.83) 0.020 30 (32.6) 0.43 (0.17,1.06) 0.066 
13-17  years 35 (29.9) 21 (25.6) 0.38 (0.14,0.98) 0.045 18 (19.6) 0.29 (0.11,0.75) 0.011 
18 and older 33 (28.2) 25 (30.5) 0.47 (0.18,1.22) 0.121 26 (28.3) 0.44 (0.17,1.11) 0.081 
Mutation types        
Large deletion 11 (9.4) 5 (6.1) baseline baseline 5 (5.4) baseline Baseline 
C terminal deletion 14 (12.0) 7 (8.5) 1.1 (0.27,4.43) 0.893 11 (12.0) 1.73 (0.46,6.47) 0.416 
Early truncating 8 (6.8) 6 (7.3) 1.65 (0.37,7.37) 0.512 3 (3.3) 0.83 (0.15,4.50) 0.824 
p.Arg106Trp 8 (6.8) 4 (4.9) 1.1 (0.22,5.45) 0.907 2 (2.2) 0.55 (0.08,3.59) 0.532 
p.Arg133Cys 8 (6.8) 6 (7.3) 1.65 (0.37,7.37) 0.512 8 (8.7) 2.2 (0.52,9.30) 0.284 
p.Arg168* 6 (5.1) 15 (18.3) 5.5 (1.33,22.73) 0.019 6 (6.6) 2.2 (0.47,10.35) 0.318 
p.Arg255* 17 (14.5) 6 (7.3) 0.78 (0.19,3.18) 0.725 7 (7.6) 0.91 (0.23,3.58) 0.888 
p.Arg270* 8 (6.8) 7 (8.5) 1.93 (0.44,8.33) 0.381 6 (6.6) 1.65 (0.37,7.37) 0.512 
p.Arg294* 7 (6.0) 4 (4.9) 1.26 (0.25,6.36) 0.782 13 (14.1) 4.09 (1.01,16.57) 0.049 
p.Arg306Cys 9 (7.7) 7 (8.5) 1.71 (0.40,7.27) 0.467 6 (6.6) 1.47 (0.33,6.43) 0.612 
p.Thr158Met 9 (7.7) 4 (4.9) 0.98 (0.20,4.76) 0.987 13 (17.4) 3.18 (0.82,12.34) 0.095 
Other 12 (10.2 11 (13.4) 2.02 (0.53,7.67) 0.304 12 (13.0) 2.2 (0.58,8.28) 0.244 
Sleep hygiene        
Total scorec - - 0.87 (0.38,1.95) 0.727 - 1.68 (0.76,3.74) 0.199 
 a
OR, odds ratio 
b 
CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes.  
 









Table 9: Univariate analyses of night laughing in relation to age group, mutation type and use of sleep hygiene strategies (n=293). 
 
 Did not occur (n=122) Sometimes (n=119) Often (n=52) 
n (%) n (%) ORa (95% CIb) p value n (%) ORa (95% CIb) p value 
Age group        
0-7 years 10 (8.2) 21 (17.6) baseline baseline 14 (26.9) baseline baseline 
8-12  years 34 (27.9) 39 (32.8) 0.55 (0.23,1.32) 0.179 16 (30.8) 0.36 (0.13,0.97) 0.043 
13-17  years 34 (27.9) 29 (24.4) 0.41 (0.16,1.00) 0.050 12 (23.1) 0.23 (0.08,0.67) 0.007 
18 and older 44 (36.1) 30 (25.2) 0.32 (0.13,0.79) 0.013 10 (19.2) 0.16 (0.53,0.47) 0.001 
Mutation type        
Large deletion 11 (9.0) 9 (7.6) baseline baseline 1 (1.9)  baseline baseline 
C terminal deletion 10 (8.2) 16 (13.4) 1.96 (0.60,6.39) 0.267 6 (11.5) 6.60 (0.67,64.76) 0.105 
Early truncating 9 (7.4%) 6 (5.0 0.81 (0.21,3.17) 0.767 2 (3.8) 2.44 (0.19,31.53) 0.493 
p.Arg106Trp 8 (6.6) 4 (3.4) 0.61 (0.14,2.71) 0.517 2 (3.8) 2.75 (0.211,35.84) 0.440 
p.Arg133Cys 7 (5.7) 8 (6.7) 1.40 (0.36,5.35) 0.626 7 (13.5) 11.00 (1.10,109.67) 0.041 
p.Arg168* 10 (8.2) 15 (12.6) 1.83 (0.56,6.03) 0.318 2 (3.8)  2.20 (0.17,28.14) 0.544 
p.Arg255* 13 (10.6) 15 (12.6) 1.41 (0.45,4.46) 0.559 3 (5.8) 2.54 (0.23,28.02) 0.447 
p.Arg270* 5 (4.1) 10 (8.4) 2.44 (0.61,9.80) 0.207 6 (11.5) 13.20 (1.24,140.68) 0.033 
p.Arg294* 13 (10.6) 3 (2.5%) 0.28 (0.06,1.31) 0.106 9 (17.3) 7.62 (0.83,69.87) 0.073 
p.Arg306Cys 11 (9.0) 9 (7.6) 1 (0.29,3.48) 1.000 2 (3.8) 2.00 (0.16,25.40) 0.593 
p.Thr158Met 12 (9.8) 9 (7.6) 0.92 (0.27,3.15) 0.890 5 (9.6) 4.58 (0.46,45.61) 0.194 
Other 13 (10.6) 15 (12.6) 1.41 (0.45,4.46) 0.559 7 (13.5) 5.92(0.63,55.85) 0.120 
Sleep hygiene        
Total scorec - - 1.31 (0.63,2.73) 0.464 - 2.62 (1.00,6.87) 0.049 
 a
OR, odds ratio 
b 
CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each participant 












Table 11: Univariate analyses of diurnal problems in relation to age group, mutation type and use of sleep hygiene strategies (n=292).                                                                                   
 
 
Did not occur 
(n=186) 
Sometimes (n=67) Often (n=39) 
n (%) n (%) ORa (95% CIb) p value n (%) ORa (95% CIb) p value 
Age group        
0-7 years 29 (15.6) 12 (17.9) baseline baseline 4 (10.2) baseline baseline 
8-12  years 56 (30.1) 21 (31.3) 0.91 (0.39,2.10) 0.818 12 (30.8) 1.55 (0.46,5.25) 0.478 
13-17  years 46 (24.7) 14 (20.9) 0.74 (0.30,1.81) 0.504 14 (35.9) 2.21 (0.66,7.36) 0.198 
18 and older 55 (29.6) 20 (29.8) 0.88 (0.38,2.05) 0.764 9 (23.1) 1.19 (0.34,4.19) 0.790 
Mutation type        
Large deletion 14 (7.5) 4 (6.0) baseline baseline 3 (7.7) baseline baseline 
C terminal deletion 24 (12.9) 6 (9.0) 0.88 (0.21,3.64) 0.854 2 (5.1) 0.39 (0.06,2.62) 0.332 
Early truncating 13 (7.0) 4 (6.0) 1.08 (0.22,5.22) 0.927 0 (0.0)  0.989 
p.Arg106Trp 13 (7.0) 1 (1.5) 0.27 (0.03,2.73) 0.267 0 (0.0)  0.990 
p.Arg133Cys 15 (8.1) 6 (9.0) 1.40 (0.33,6.03) 0.651 1 (2.6) 0.31 (0.03,3.35) 0.336 
p.Arg168* 13 (7.0) 6 (9.0) 1.62 (0.37,7.05) 0.523 7 (17.9) 2.51 (0.53,11.82) 0.244 
p.Arg255* 22 (11.8) 8 (11.9) 1.27 (0.32,5.03) 0.731 1 ((2.6) 0.21 (0.02,2.25) 0.198 
p.Arg270* 10 (5.4) 6 (9.0) 2.10 (0.47,9.44) 0.333 5 (12.8) 2.33 (0.45,12.09) 0.313 
p.Arg294* 10 (5.4) 9 (13.4) 3.15 (0.75,13.17) 0.116 6 (15.4) 2.80 (0.56,13.95) 0.209 
p.Arg306Cys 14 (7.5) 7 (10.4) 1.75 (0.42,7.35) 0.445 2 (5.1) 0.67 (0.10,4.62) 0.681 
p.Thr158Met 14 (7.5) 5 (7.5) 1.25 (0.28,5.65) 0.772 6 (15.4) 2.00 (0.42,9.63) 0.387 
Other 24 (12.9) 5 (7.5) 0.73 (0.17,3.17) 0.674 6 (15.4) 1.17 (0.25,5.41) 0.844 
Sleep hygiene        
Total scorec - - 1.31 (0.58,2.95) 0.511 - 1.37 (0.50,3.73) 0.537 
a
OR, odds ratio 
b 
CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each participant 
‘*’ represents the stop codons of the related genotypes. 
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Table 13: Univariate analyses of teeth grinding in relation to age group, mutation type and use of sleep hygiene strategies (n=291). 
 
 
Teeth grinding (n=291) 
Did not occur 
(n=157) 
Sometimes (n=58) Often (n=76) 
n  n ORa (95% CIb) p value n ORa (95% CIb) p value 
Age groups        
0-7 years 19 8 baseline baseline 18                         baseline baseline 
8-12  years 51 20 0.93 (0.35,2.47) 0.886 19 0.39 (0.17,0.90) 0.028 
13-17  years 38 16 1 (0.36,2.75) 1.00 17 0.47 (0.20,1.11) 0.088 
18 and older 49 14 0.68 (0.25,1.88) 0.455 22 0.47 (0.21,1.07) 0.073 
Mutation types        
Large deletion 11 4 baseline baseline 6 baseline baseline 
C terminal deletion 19 8 1.16 (0.28,4 75) 0.839 5 0.48 (0.12,1.96) 0.308 
Early truncating 9 3 0.92 (0.16,5.21) 0.922 4 0.81 (0.17,3.81) 0.795 
p.Arg106Trp 11 0 0 0.974 2 0.33 (0.05,2.003) 0.233 
p.Arg133Cys 7 4 1.57 (0.29,8.42) 0.598 10 2.62 (0.65,10.48) 0.173 
p.Arg168* 13 5 1.06 (0.23,4.94) 0.943 9 1.27 (0.34,4.70) 0.721 
p.Arg255* 18 9 1.38 (0.34,5.56) 0.655 4 0.41 (0.09,1.77) 0.232 
p.Arg270* 11 4 1 (0.20,5.04) 1.00 6 1 (0.24,4.08) 1.00 
p.Arg294* 14 1 0.20 (0.02,2.02) 0.171 10 1.31 (0.36,4.73) 0.680 
p.Arg306Cys 15 3 0.55 (0.10,2.97) 0.487 5 0.61 (0.15,2.53) 0.496 
p.Thr158Met 12 4 0.92 (0.18,4.58) 0.916 10 1.52 (0.42,5.61) 0.532 
Other 17 13 2.10 (0.54,8.14) 0.282 5 0.54 (0.13,2.21) 0.390 
Sleep hygiene        
Total scorec - - 0.80 (0.33,1.90) 0.608 - 0.77 (0.35,1.69) 0.510 
a
OR, odds ratio 
b 
CI, confidence interval 
c calculated by taking the average of the total score divided by the number of questions responded by each participant 
















Average of total scores  
n Coefficient (95% CIa) p value 
Age groups 
0-7 years 39                baseline - 
8-12  years 86          -1.22 (-2.25,-0.20) 0.020 
13-17  years 64   -1.04 (-2.12,0.05) 0.060 
18 and older 78 -1.70 (-2.74,-0.65) 0.002 
Mutation types 
Large deletion 19                                                             baseline - 
C terminal deletion 29          -0.10 (-1.69,1.50) 0.906 
Early truncating 16 -0.40 (-2.24,1.43) 0.666 
p.Arg106Trp 13 -0.21 (-2.15,1.74) 0.833 
p.Arg133Cys 19    0.30 (-1.45,2.05) 0.737 
p.Arg168* 24 0.11 (-1.55,1.77) 0.898 
p.Arg255* 27   -0.15 (-1.77,1.46) 0.851 
p.Arg270* 19   0.34 (-1.41,2.09) 0.703 
p.Arg294* 22   1.52 (-0.18,3.20) 0.080 
p.Arg306Cys 21 -0.24 (-1.95,1.47) 0.783 
p.Thr158Met 23 0.99 (-0.68,2.67) 0.244 
Other 35 0.89 (-0.65,2.43) 0.254 
Epilepsy 
No/ completely under control   117                           baseline - 
Rarely has a seizure any more (once or twice per 
year) 
30          0.75 (-0.34,1.85) 0.177 
Has occasional seizures (once per month) 40 -0.36 (-1.34,0.62) 0.471 
Seizures occur frequently (once per week) 40 -0.33 (-1.31,0.65) 0.512 
Seizures are not controlled (daily/more than once a 
week) 
37 1.40 (0.39,2.40) 0.007 
Scoliosis 
No  84                  baseline - 
Mild 85          -0.44 (-1.27,0.39) 0.293 
Severe 26 0.05 (-1.16,0.26) 0.940 
Surgery 61 -0.66 (-1.57,0.24) 0.151 
Mobility 
Walks with no assistance  110                   baseline - 
Walks with assistance  75 0.41 (-0.40,1.22) 0.317 
Unable to walk 82 0.52 (-0.27,1.31) 0.196  










DIMS SWTD DOES 
n Coefficient 
 (95% CIa) 
p value n Coefficient 
 (95% CIa) 
p value n Coefficient 
 (95% CIa) 
p value 
Age groups 
0-7 years 39 baseline - 39 - - 39 - - 
8-12  years 86 -0.18 (-0.45,0.10) 0.214 86 -0.41 (-0.69,-0.13) 0.005 86 -0.10 (-0.39,0.19) 0.484 
13-17  years 64 -0.05  (-0.34,0.24) 0.724 64 -0.50 (-0.80,-0.21) 0.001 64 -0.13 (-0.44,0.17) 0.390 
18 and older 78 -0.15  (-0.43,0.13) 0.297 78 -0.63 (-0.91,-0.34) 0.000 78 -0.30 (-0.59,-0.00) 0.047 
Mutation types 
Large deletion 19 baseline - 19 - - 19 - - 
C terminal deletion 29 -0.00 (-0.41,0.41) 0.985 16 0.01 (-0.43,0.45) 0.976 29 0.09 (-0.36,0.53) 0.698 
Early truncating 16 -0.12 (-0.59,0.35) 0.610 13 -0.02 (-0.53,0.48) 0.929 16 -0.33 (-0.83,0.18) 0.209 
p.Arg106Trp 13 0.03 (-0.47,0.53) 0.913 19 -0.34 (-0.87,0.20) 0.217 13 -0.30 (-0.84,0.24) 0.278 
p.Arg133Cys 19 0.07 (-0.38,0.52) 0.764 24 0.38 (-0.11,0.86) 0.127 19 -0.26 (-0.75,0.23) 0.293 
p.Arg168* 24 0.02 (-0.41,0.44) 0.936 27 -0.17 (-0.63,0.29) 0.469 24 0.08 (-0-.38,0.54) 0.746 
p.Arg255* 27 -0.05 (-0.47,0.37) 0.812 19 -0.25 (-0.70,0.19) 0.267 27 -0.18 (-0.63,0.27) 0.437 
p.Arg270* 19 0.12 (-0.33,0.57) 0.606 22 -0.13 (-0.62,0.35) 0.586 19 0.11 (-0.38,0.60) 0.655 
p.Arg294* 22 0.72 (0.29,1.16) 0.001 29 0.23 (-0.23,0.70) 0.324 22 0.15 (-0.32,0.62) 0.535 
p.Arg306Cys 21 0.14 (-0.30,0.58) 0.535 21 -0.03 (-0.50,0.45) 0.915 21 -0.29 (-0.76,0.19) 0.232 
p.Thr158Met 23 0.52 (0.09,0.95) 0.019 23 0.17 (-0.29,0.63) 0.471 23 -0.03 (-0.49,0.44) 0.911 
Other 35 0.27 (-0.13,0.67) 0.182 35 0.01 (-0.42,0.43) 0.981 35 0.14 (-0.29,0.57) 0.519 
Epilepsy 
No/ completely under control 117 baseline - 117 - - 117 - - 
Rarely has a seizure any more (once or twice per year) 30 0.28 (-0.01,0.58) 0.058 30 -0.22(-0.52,0.09) 0.164 30 0.27 (-0.02,0.57) 0.067 
Has occasional seizures (once per month) 40 -0.18 (-0.45,0.08) 0.168 40 -0.31 (-0.58,-0.03) 0.029 40 0.23 (-0.04,0.49) 0.091 
Seizures occur frequently (once per week) 40 -0.12 (-0.38,0.14) 0.375 40 -0.29 (-0.57,-0.02) 0.037 40 0.18 (-0.08,0.45) 0.169 
Seizures are not controlled (daily/more than once a week) 37 0.08 (-0.19,0.35) 0.563 37 -0.00 (-0.28,0.28) 0.996 37 0.82 (0.55,1.09) 0.000 
Scoliosis 
No 84 baseline - 84 - - 84 - - 
Mild 85 -0.06 (-0.28,0.16) 0.612 85 -0.26 (-0.48,-0.04) 0.023 85 0.04 (-0.19,0.27) 0.726 
Severe 26 -0.07 (-0.39,0.25) 0.672 26 -0.14 (-0.46,0.18) 0.396 26 0.12 (-0.22,0.45) 0.495 
Surgery 61 -0.15 (-0.39,0.09) 0.227 61 -0.51(-0.75,-0.27) 0.000 61 0.00 (-0.25,0.26) 0.983 
Mobility 
Walks with no assistance  110 baseline - 110 - - 110 - - 
Walks with assistance  75 -0.08 (-0.29,0.14) 0.486 75 -0.23 (-0.45,-0.00) 0.049 75 0.22 (-0.00,0.44) 0.052 
Unable to walk 82 -0.18 (-0.39,0.03) 0.093 82 -0.23 (-0.45,-0.02) 0.035 82 0.36 (0.15,0.58) 0.001 
 
a CI, confidence interval 
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